Heterocyclic compound and use thereof
Patent Information
- Application Number
- MYPI2025004910
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-29
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-02
AI Technical Summary
There is a need for new therapeutic agents for central nervous system diseases, particularly for conditions like schizophrenia, where existing treatments may not be effective or have limitations in efficacy and metabolism.
Development of novel heterocyclic compounds and their salts, specifically represented by Formula (I), which act as dopamine D2 receptor partial agonists, serotonin 5-HT2A receptor antagonists, and adrenaline α1 receptor antagonists, with serotonin uptake inhibitory effects, offering improved properties and therapeutic options for central nervous system diseases.
The novel heterocyclic compounds provide effective therapeutic agents for a wide range of central nervous system diseases, including treatment-resistant schizophrenia, by modulating neurotransmitter activity and potentially offering improved metabolic stability and efficacy.
Smart Images

Figure PI2025004910_DRAWING_001 
Figure PI2025004910_DRAWING_002 
Figure PI2025004910_DRAWING_003
Abstract
Description
Heterocyclic compounds and their uses
[0001] The present disclosure relates to specific heterocyclic compounds and uses thereof.
[0002] 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (hereinafter also referred to as brexpiprazole) or a salt thereof is a compound used in the treatment of dopamine D 2 Receptor partial agonist action, serotonin 5-HT 2A Receptor antagonism and adrenaline alpha 1 In addition to these effects, brexpiprazole or a salt thereof also has a serotonin uptake inhibitory effect (or a serotonin reuptake inhibitory effect), and is known to have a wide therapeutic spectrum for central nervous system disorders (particularly schizophrenia) (e.g., Patent Documents 1 and 2).
[0003] One approach to drug design in the pharmaceutical field is to develop drugs that aim to improve the properties of known drug molecules (for example, to improve their efficacy or slow their metabolism in vivo) by chemically converting or modifying some of the functional groups of the molecules.
[0004] It is highly desirable to carry out such pharmaceutical development for brexpiprazole as well, thereby finding new compounds with improved properties and providing new options for therapeutic drugs for central nervous system diseases.
[0005] Patent Document 1: JP 2006-316052 A, International Publication No. 2013 / 035892
[0006] One of the problems to be solved by the present disclosure is to provide a novel therapeutic agent for central nervous system diseases.
[0007] As a result of extensive research, the present inventors have discovered a compound represented by the following formula (I):
[0008] We have succeeded in developing a novel heterocyclic compound and its salt, which are represented by the formula: and have found that they may become novel therapeutic agents for central nervous system diseases.
[0009] The present disclosure includes, for example, the subject matter described in the following sections:
[0010] Item 1. Formula (I): (In the formula, R 1 , R 2 are each independently -O - , -OR 4 , or -NR 4Na R 4Nb indicates, R 3 represents hydrogen or alkyl, R 4 , R 4Na , and R 4Nb each independently represents hydrogen, or an alkyl, alkenyl, alkadienyl, or alkynyl group which may have 1 to 3 substituents, and R 4 , R 4Na , and R 4Nb The alkyl represented by is a methylene group (-CH 2 -) is -O-, -S-, -CO-, -NH-, -SiR sia R sib - or -(CO)O- may be substituted, and the R 1 and R 2 Both - OR 4 When R indicates 1 and R 2 may be the same or different, and 1 and R 2 Both are -NR 4Na R 4Nb When R indicates 1 and R 2 may be the same or different.) A compound or a salt thereof represented by the following item 2. R 1 Ga-O - indicates R 2 Ga-OR 4 , or -NR 4Na R 4Nb (R 4 , R 4Na , and R 4Nb (wherein is the same as above), the compound or salt thereof according to item 1. Item 3. A compound of formula (I): (In the formula, R 1 Ga-O - indicates R 2 Ga-OR4 , or -NR 4Na R 4Nb indicates, R 3 is hydrogen or C 1-6 represents alkyl, R 4 represents hydrogen or any of the following (0-1) to (5): 4Na R 4Nb represents the following (i) or (ii): (0-1): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 Alkenyl, (0-2): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 Alkadienyl, (0-3): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 Alkynyl, (1-1): R 4a1 indicates, R 4a1 is -C n H 2n+1 , -C n H 2n-1 , -C n H 2n-3 , -C n H 2n —OH, —C n H 2n-2 -OH, or -C n H 2n-4 (In the above formula, n represents 1 to 24. However, -C n H 2n-1 So n is 2 or more, -C n H 2n-3 So n is 2 or more, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 -n is 2 or more.) (1-2):R 4a2 indicates, R 4a2 is -CHX 1 X 2 -Cn-1 H 2n-2 -CHX 1 X 2 -C n-1 H 2n-4 -CHX 1 X 2 , or -C n-1 H 2n-6 -CHX 1 X 2 (In the above formula, n represents 2 to 24. However, -C n-1 H 2n-4 -n is 3 or more, -C n-1 H 2n-5 -n is 3 or more. X 1 and X 2 are the same or different and represent a hydrogen atom or a halogen atom (F, Cl, Br, or I). 1 and X 2 At least one of the groups represents a halogen.) (1-3): R 4a3 indicates, R 4a3 is -C n H 2n -R 4-1 , -C n-1 H 2n-2 -CHR 4-1a R 4-1b , -C n H 2n-2 -R 4-1 , or -C n H 2n-4 -R 4-1 (In the above formula, n represents 1 to 24. However, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 -n is 2 or more. 4-1 is C 1-6 Alkoxy, —O-phenyl, or C 1-6 R represents a heterocyclic group optionally substituted with alkyl or halogen. 4-1a and R 4-1b , are the same or different, -C 1-3 Alkylene-C 1-3 or, the same or different, represents an alkoxy; 1-3 Alkyl, or —CH 2-CO-O-C 1-3 (2): R 4b indicates, R 4b is -(C p H 2p -O) q -C r H 2r -R 4-2 , -(C p H 2p -O) q -C r H 2r-2 -R 4-2 , -(C p H 2p-2 -O) q -C r H 2r -R 4-2 , or -(C p H 2p-2 -O) q -C r H 2r-2 -R 4-2 (In the above formula, p represents 1 to 4, q represents 1 to 4, and r represents 1 to 4. However, C p H 2p-2 So p is 2 or more, C r H 2r-2 In the formula, r is 2 or more. When q is 2 to 4, the 2 to 4 repeating structures representing the number of repetitions represented by q may be the same or different. 4-2 is a hydrogen atom, hydroxy, or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (3): -C represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. α H 2α -CO-O-R COO Or -C α H 2α —CO—O—CH 2 -R COO (α represents 1 to 10), and -R COO is a hydrogen atom, 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 Alkyl or C1-6 Alkoxy or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (4): -C represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. β H 2β -O-CO-R OCO (β represents 1 to 10), and -R OCO is R 4a1 , R 4b , or -C α H 2α -CO-O-R COO or -C α H 2α —CO—NH—R COO , -C α H 2α -NH-CO-R COO , or -C α H 2α -NH-CO-OR COO or (-R COO is the same as above) or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (5): -C represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. γ H 2γ -O-CO-O-R OCOO (γ represents 1 to 10), and -R OCOO is a hydrogen atom, R 4a1 , R 4b , or -C α H 2α -CO-O-R COO or (-R COO is the same as above) or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3(i): R represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. 4Na and R 4Nb are the same or different, and each is 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 (ii): R 4Na is a hydrogen atom, and R 4Nb is 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 represents alkyl or -C α H 2α -CO-O-R COO , or -C α H 2α —CO—NH—R COO (-R COO Item 4. A compound or salt thereof represented by the following formula: (wherein -OR is the same as above). Item 5. The compound or salt thereof according to any one of Items 1 to 3, wherein the heterocyclic group is a group having a structure in which one hydrogen atom bonded to an atom constituting a heterocycle selected from furan, tetrahydropyran, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, pyrrole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrolidine, imidazolidine, thiophene, piperidine, piperazine, oxazole, isoxazole, oxadiazole, morpholine, indole, indazole, benzimidazole, and quinoline has been removed. Item 6. -OR 4 is the R of the oxygen atom 4 The opposite side is indicated by * (*-OR 4 ) is one of the groups shown in the table below, -NR 4Na R 4Nb is R of the nitrogen atom 4Na R 4Nb The opposite side is indicated by * (*-NR 4Na R4Nb ) is any of the groups shown in the table below: Item 6. A compound or salt thereof according to any one of Items 1 to 4. Item 6. A pharmaceutical composition comprising a compound or salt thereof according to any one of Items 1 to 5, and a pharmaceutically acceptable carrier. Item 7. The pharmaceutical composition according to Item 6, which is in the form of a suspension, comprising a compound or salt thereof according to any one of Items 1 to 5, a suspending agent, and a dispersion medium. Item 8. The pharmaceutical composition according to Item 7, wherein the particles in the suspension have an average particle size of 0.5 to 30 μm. Item 9. The pharmaceutical composition according to Item 7, wherein the particles in the suspension have an average particle size of 50 to 500 nm. Item 10. The pharmaceutical composition according to any one of Items 7 to 9, wherein the suspending agent is carboxymethylcellulose or a salt thereof, and the dispersion medium is a liquid containing water for injection. Item 11. A pharmaceutical composition comprising a viscous mixture of a) the compound or salt thereof according to any one of Items 1 to 5, b) multiple types of liquid crystal-forming lipids or gel-forming lipids, and c) a biocompatible organic solvent, said pharmaceutical composition being a precursor formulation used to form a liquid crystal phase structure or a lipid gel upon contact with aqueous fluid in a living body. Item 12. The pharmaceutical composition according to Item 11, wherein b) the multiple liquid crystal-forming lipids or gel-forming lipids comprise b-1) at least one type of diacylglycerol, and b-2) at least one type of phosphatidylcholine. Item 13. A pharmaceutical composition comprising a viscous mixture of a) the compound or salt thereof according to any one of Items 1 to 5, b-1) at least one type of diacylglycerol, b-2) at least one type of phosphatidylcholine, and c) a biocompatible organic solvent. Item 14. Microspheres containing the compound or salt thereof according to any one of Items 1 to 5 as an active ingredient. Item 15. Microspheres according to Item 14, comprising the compound according to any one of Items 1 to 5 and a biodegradable polymer. Item 16. Microspheres according to Item 15, wherein the biodegradable polymer is at least one selected from the group consisting of polylactic acid and lactic acid-glycol copolymer. Item 17. Microspheres according to any one of Items 14 to 16, having an average particle size of 5 to 150 μm (preferably 30 to 100 μm). Item 18. A pharmaceutical composition comprising the microspheres according to any one of Items 14 to 17 in a suspended state. Item 19. A pharmaceutical composition comprising the microspheres according to any one of Items 14 to 17 in a suspended state in oil.Item 20. The pharmaceutical composition according to Item 19, wherein the oil is a medium-chain fatty acid triglyceride. Item 21. The pharmaceutical composition according to any one of Items 6 to 13 and 18 to 20, which is for intramuscular or subcutaneous administration. Item 22. The pharmaceutical composition according to any one of Items 6 to 13 and 18 to 21, which is for the prevention and / or treatment of a central nervous system disease. Item 23. The central nervous system disease is selected from the group consisting of schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment, and the like. Item 22. The pharmaceutical composition according to Item 22, wherein the central nervous system disorder is selected from the group consisting of cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment due to schizophrenia, cognitive impairment caused by treatment-resistant, intractable, or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia, and borderline personality disorder. Item 24. The pharmaceutical composition according to any of Items 6 to 13 and 18 to 23, wherein the pharmaceutical composition is administered at intervals of 1 day or 2 to 3 days. Item 25. The pharmaceutical composition according to any of Items 6 to 13 and 18 to 23, wherein the pharmaceutical composition is administered at intervals of 2 weeks or more. Item 26. The pharmaceutical composition according to any of Items 6 to 13 and 18 to 23, wherein the pharmaceutical composition is administered at intervals of 4 weeks or more. Item 27. A preventive and / or therapeutic agent for central nervous system disorders, comprising the compound or salt thereof according to any one of items 1 to 5 as an active ingredient.Item 28. The central nervous system disease is schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive disorder, Item 27. The prophylactic and / or therapeutic agent for a central nervous system disorder selected from the group consisting of cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment due to schizophrenia, cognitive impairment caused by treatment-resistant, intractable, or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia, and borderline personality disorder. Item 29. Use of the compound or a salt thereof according to any one of Items 1 to 5 as a pharmaceutical. Item 30. A method for preventing and / or treating a central nervous system disorder, comprising administering the compound or a salt thereof according to any one of Items 1 to 5 to a human or animal. Item 31. Central nervous system diseases include schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatic disorder, Item A-1. The method for preventing and / or treating a central nervous system disorder selected from the group consisting of: actual or suspected psychosis, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment, cognitive impairment associated with neurodegenerative disease, cognitive impairment caused by neurodegenerative disease, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, intractable or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia, and borderline personality disorder. (In the formula, R 1 , R 2 are each independently -O - Or -OR 4 indicates, R3 represents hydrogen or alkyl, R 4 represents hydrogen or alkyl optionally having 1 to 3 substituents, and the R 4 In the alkyl represented by R, some carbon atoms may be replaced by -O- and / or -(CO)O-, 1 and R 2 Both - OR 4 In this case, the R 4 may be the same or different.) A compound represented by the formula (I) or a salt thereof. 4 The alkyl represented by the formula (I) is such that the carbon atom of the terminal methyl group is replaced by —O— or —(CO)O—, and one side of the —O— or —(CO)O— is substituted with a substituent R C1 is bonded to the R C1 represents hydrogen, lower alkyl, an optionally substituted cycloalkyl, or an optionally substituted heterocyclic group. Item A-3. The compound or salt thereof according to Item A-1, wherein the substituent in the alkyl which may have 1 to 3 substituents is (i) a substituent bonded to a carbon atom of the alkyl, or (ii) a substituent (R C1 ) wherein the substituent in (i) is halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyl, carboxy, lower alkylaminocarbonyl, or a heterocyclic group which may have a substituent; and the substituent in (ii) (R C1 Item A-4. The compound or salt thereof according to Item A-1 or A-2, wherein R 1 is a substituted or unsubstituted alkyl group, R 2 is a substituted or unsubstituted cycloalkyl group, or R 3 is a substituted or unsubstituted heterocyclic group. Item A-5. The compound or salt thereof according to Item A-4, wherein the compound represented by formula (I) is a compound represented by formula (II): (In the formula, R 3 and R 4 The compound or salt thereof according to any one of Items A-1 to A-3, wherein R is a compound represented by the formula (I) or (II), and R is the same as above. 3 is hydrogen or C 1-6 R indicates alkyl 4 is hydrogen or C optionally having 1 to 3 substituents 1-18 represents alkyl, and the R4 In the alkyl represented by R, 1 to 5 carbon atoms may be replaced by -O- and / or -(CO)O-, 1 and R 2 Both - OR 4 In this case, the R 4 may be the same or different, the compound or salt thereof according to any one of Items A-1 to A-4. Item A-6. R 4 is hydrogen or optionally has 1 to 3 substituents, C 1-18 alkyl, each of the substituents independently being hydrogen, halogen, hydroxy, lower alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , -(CO)NR 7 R 8 , —O(CO)R 9 , -O(CO)OR 10 , -O(CO)(CR 11 R 12 ) n (CO)OR 13 , C 3-7 represents a cycloalkyl or an optionally substituted heterocyclic group, 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 Alkyl, or C 3-7 represents cycloalkyl, R 7 and R 8 each independently represents a hydrogen atom or a lower alkyl in which one or two carbon atoms may be replaced by an oxygen atom or a nitrogen atom; R 7 and R 8 may be bonded to form a ring, R 11 and R 12 are independently, and R 11 When there are multiple R 12When a plurality of groups are present, each group independently represents a hydrogen atom or C. 1-16 alkyl, n is an integer from 1 to 10 (1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), 1 and R 2 Both - OR 4 In this case, the R 4 may be the same or different, the compound or salt thereof according to any one of Items A-1 to A-5. Item A-7. R 4 is hydrogen or -(AY) m -R 14 A indicates C 1-18 represents alkylene, Y represents a bond, —O—, —(CO)O—, —O(CO)O—, or —(CO)NH—, and R 14 is hydrogen, C 1-18 A compound or a salt thereof according to any one of Items A-1 to A-6, wherein R represents an alkyl, hydroxy, cycloalkyl, or heterocyclic group, and m represents an integer of 0 to 5 (0, 1, 2, 3, 4, or 5). Item A-8. R 4 is hydrogen or optionally has one substituent, C 1-8 alkyl, each of the substituents independently being hydroxy, lower alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , —O(CO)R 9 , -O(CO)OR 10 , -O(CO)-A-(CO)OR 13 , or two Cs 1-6 morpholinyl optionally having alkyl, n is an integer of 1 to 10, 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 alkyl, a heterocyclic group which may have a substituent, or C 3-7 represents cycloalkyl, and A is C 1-6The compound or salt thereof according to any one of Items A-4 to A-6, wherein R represents alkylene. 4 is hydrogen or optionally has one substituent, C 1-8 alkyl, each of the substituents independently being hydroxy, C 1-6 Alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , —O(CO)R 9 , -O(CO)-A-(CO)OR 13 , or two Cs 1-6 represents a heterocyclic group optionally having an alkyl group, and n represents an integer of 1 to 10, wherein R 5 is C 1-6 Alkyl, R 5a is C 1-6 Alkyl, R 6 is C 1-6 Alkyl, R 9 is C 1-16 Alkyl, R 13 is C 1-6 Alkyl or C 1-6 A represents a pyridyl group optionally having alkyl groups, and A represents C 1-6A compound or a salt thereof according to any one of Items A-4 to A-6, wherein the heterocyclic group is a heterocyclic group selected from furan, tetrahydropyran, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, pyrrole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrolidine, imidazolidine, thiophene, piperidine, piperazine, oxazole, isoxazole, oxadiazole, morpholine, indole, indazole, benzimidazole, and quinoline, with one hydrogen atom removed from the heterocyclic atom. A pharmaceutical composition comprising a compound or a salt thereof according to any one of Items A-1 to A-10, and a pharmaceutically acceptable carrier. Item A-12. The pharmaceutical composition according to Item A-11, which is in the form of a suspension, comprises a compound or salt thereof according to any one of Items A-1 to A-10, a suspending agent, and a dispersion medium. Item A-13. The pharmaceutical composition according to Item A-12, wherein the average particle size of the particles in the suspension is 0.5 to 30 μm. Item A-14. The pharmaceutical composition according to Item A-12, wherein the average particle size of the particles in the suspension is 50 to 500 nm. Item A-15. The pharmaceutical composition according to any one of Items A-12 to A-14, wherein the suspending agent is carboxymethylcellulose or a salt thereof, and the dispersion medium is a liquid containing water for injection. Item A-16. A pharmaceutical composition comprising a viscous mixture of a) a compound or salt thereof according to any one of Items A-1 to A-10, b) multiple types of liquid crystal-forming lipids or gel-forming lipids, and c) a biocompatible organic solvent, which is a precursor formulation used to form a liquid crystal phase structure or a lipid gel when brought into contact with an aqueous fluid in a living body. Item A-17. The pharmaceutical composition according to Item A-16, wherein the liquid crystal-forming lipids or gel-forming lipids comprise: b-1) at least one diacylglycerol; and b-2) at least one phosphatidylcholine. Item A-18. A pharmaceutical composition comprising a viscous mixture of: a) a compound according to any one of Items A-1 to A-10 or a salt thereof; b-1) at least one diacylglycerol; b-2) at least one phosphatidylcholine; and c) a biocompatible organic solvent.Item A-19. Microspheres containing the compound or salt thereof according to any one of Items A-1 to A-10 as an active ingredient. Item A-20. Microspheres according to Item A-19, containing the compound according to any one of Items A-1 to A-10 and a biodegradable polymer. Item A-21. Microspheres according to Item A-20, wherein the biodegradable polymer is at least one selected from the group consisting of polylactic acid and lactic acid-glycol copolymer. Item A-22. Microspheres according to any one of Items A-19 to A-21, having an average particle size of 5 to 150 μm (preferably 30 to 100 μm). Item A-23. A pharmaceutical composition containing the microspheres according to any one of Items A-19 to A-22 in a suspended state. Item A-24. A pharmaceutical composition containing the microspheres according to any one of Items A-19 to A-22 in a suspended state in oil. Item A-25. A pharmaceutical composition wherein the oil according to Item A-24 is a medium-chain fatty acid triglyceride. Item A-26. A pharmaceutical composition according to any one of Items A-11 to A-18 and A-23 to A-25, which is used for intramuscular or subcutaneous administration. Item A-27. A pharmaceutical composition according to any one of Items A-11 to A-18 and A-23 to A-26, which is used for the prevention and / or treatment of central nervous system diseases. Item A-28. An agent for the prevention and / or treatment of central nervous system diseases, which comprises as an active ingredient a compound according to any one of Items A-1 to A-10 or a salt thereof. Item A-29. Central nervous system diseases include schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment, The prophylactic and / or therapeutic agent according to Item A-28, which is for a central nervous system disorder selected from the group consisting of cognitive impairment associated with a neurodegenerative disease, cognitive impairment caused by a neurodegenerative disease, cognitive impairment due to schizophrenia, cognitive impairment caused by treatment-resistant, intractable or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia and borderline personality disorder.Item A-30. Use of the compound according to any one of Items A-1 to A-10 or a salt thereof as a medicine. Item A-31. A method for preventing and / or treating central nervous system diseases, which comprises administering to a human or animal the compound according to any one of Items A-1 to A-10 or a salt thereof. Item A-32. A method for preventing and / or treating central nervous system diseases, which comprises administering to a human or animal the compound according to any one of Items A-1 to A-10 or a salt thereof, The method for preventing and / or treating the central nervous system disorder according to Item A-31, wherein the central nervous system disorder is selected from the group consisting of present-apparent disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment, cognitive impairment associated with neurodegenerative disease, cognitive impairment caused by neurodegenerative disease, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, intractable or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia and borderline personality disorder. In the above sections, the heterocycle of the heterocyclic group, which may have a substituent, includes a saturated or unsaturated monocyclic or polycyclic heterocycle containing 1 to 5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur as ring-constituting atoms, such as a saturated or unsaturated 3- to 15-membered, preferably 5- to 10-membered, monocyclic, bicyclic, or tricyclic heterocycle. Specific examples include furan, tetrahydropyran, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, pyrrole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrolidine, imidazolidine, thiophene, piperidine, piperazine, oxazole, isoxazole, oxadiazole, morpholine, indole, indazole, benzimidazole, and quinoline. The heterocyclic group is a group having a structure in which one hydrogen atom bonded to an atom constituting the heterocycle is removed from the heterocycle.In the above items, the substituent in the heterocyclic group which may have a substituent is halogen, hydroxy, or halogen, hydroxy, oxo, or C. 1-6 C optionally substituted with alkoxy 1-6 C optionally substituted with alkyl, halogen, hydroxy or oxo 1-6 The number of the substituents may be, for example, 1, 2, or 3.
[0011] The compound represented by formula (I) has a structure in which a specific nitrogen atom of brexpiprazole is chemically modified, and after being administered to a living body, the compound represented by formula (I) can be converted to brexpiprazole under physiological conditions.
[0012] The compounds represented by formula (I) include (1) compounds with relatively low cytotoxicity. The compounds represented by formula (I) also include (2) compounds with high stability and ease of handling. The compounds represented by formula (I) also include (3) compounds with relatively rapid subcutaneous absorption. The compounds represented by formula (I) also include (4) compounds that are rapidly converted to brexpiprazole in vivo. The compounds represented by formula (I) also include (5) compounds suitable for injections, particularly subcutaneous injections. The compounds represented by formula (I) also include (6) compounds suitable for sustained release injections, particularly subcutaneous sustained release injections, that maintain blood brexpiprazole concentrations for at least one week to at least four weeks.
[0013] 1 shows the plasma drug concentration profile after subcutaneous administration of the pharmaceutical composition of Example A to rats (dosage: 1.25 mg / kg) (n=3, mean ± standard deviation). 2 shows the plasma drug concentration profile after subcutaneous administration of the pharmaceutical composition of Example D (aqueous suspension of the compound of Example 1) to rats (dosage: 31.3 mg / kg) (N=3, mean ± standard deviation). 3 shows the plasma drug concentration profile after subcutaneous administration of the pharmaceutical composition of Example E (aqueous suspension of the zinc salt of the compound of Example 1) to rats (dosage: 33.2 mg / kg) (N=3, mean ± standard deviation). 4 shows the plasma drug concentration profile after subcutaneous administration of the pharmaceutical composition of Example F (liquid crystal / lipid gel formulation of the compound of Example 1) to rats (dosage: 31.3 mg / kg) (N=3, mean ± standard deviation). 1 shows the time course of plasma drug concentration (dosage: 33.2 mg / kg) when the pharmaceutical composition of Example G (a zinc salt liquid crystal / lipid gel formulation of the compound of Example 1) was administered subcutaneously to rats (N=3, mean±standard deviation). 1 shows the results of polarizing microscope observation of the microspheres of Production Example I. 1 shows the results of polarizing microscope observation of the microspheres of Production Example J. 1 shows the results of polarizing microscope observation of the microspheres of Production Example K. 1 shows the time course of plasma drug concentration (dosage: 31.3 mg / kg) when the pharmaceutical composition of Example H (a microsphere formulation of the compound of Example 1 (RG505, 1.5-fold API ratio)) was administered subcutaneously to rats (N=5 until day 14, N=3 from day 21 onwards, mean±standard deviation). 1 shows the time course of plasma drug concentration (dosage: 31.3 mg / kg) when the pharmaceutical composition of Example J (microsphere formulation of the compound of Example 1 (RG504, 2-fold API ratio)) was administered subcutaneously to rats (N=5 until day 14, N=3 from day 21 onwards, mean ± standard deviation). FIG. 1 shows the time course of plasma drug concentration (dosage: 31.3 mg / kg) when the pharmaceutical composition of Example K (microsphere formulation of the compound of Example 1 (RG503, 1.5-fold API ratio)) was administered subcutaneously to rats (N=5 until day 14, N=3 from day 21 onwards, mean ± standard deviation). FIG. 1 shows the time course of plasma drug concentration (dosage: 31.3 mg / kg) when the pharmaceutical composition of Example L (microsphere formulation of the compound of Example 1 (RG503, 2-fold API ratio)) was administered subcutaneously to rats (N=3, mean ± standard deviation).Figure 1 shows the plasma drug concentration profile (dose: 29.8 mg / kg) after subcutaneous administration of the pharmaceutical composition of Example P (aqueous suspension of the compound of Example 3) to rats (N=5, mean ± standard deviation). Figure 2 shows the plasma drug concentration profile (dose: 35.5 mg / kg) after subcutaneous administration of the pharmaceutical composition of Example Q (aqueous suspension of the compound of Example 10) to rats (N=3, mean ± standard deviation). Figure 3 shows the plasma drug concentration profile (dose: 34.7 mg / kg) after subcutaneous administration of the pharmaceutical composition of Example R (aqueous suspension of the compound of Example 12) to rats (N=3, mean ± standard deviation). Figure 4 shows the plasma drug concentration profile (dose: 36.3 mg / kg) after subcutaneous administration of the pharmaceutical composition of Example S (aqueous suspension of the compound of Example 13) to rats (N=3, mean ± standard deviation). 1 shows the time course of the drug concentration in plasma when the pharmaceutical composition of Example T (aqueous suspension of the compound of Example 44) was administered subcutaneously to rats (dosage: 37.1 mg / kg) (N=3, mean ± standard deviation). 2 shows the time course of the drug concentration in plasma when the pharmaceutical composition of Example U (aqueous suspension of the compound of Example 92) was administered subcutaneously to rats (dosage: 36.3 mg / kg) (N=3, mean ± standard deviation). 3 shows the time course of the drug concentration in plasma when the pharmaceutical composition of Example V (aqueous suspension of the compound of Example 121) was administered subcutaneously to rats (dosage: 37.1 mg / kg) (N=3, mean ± standard deviation).
[0014] Each embodiment included in the present disclosure will be described in more detail below. The present disclosure preferably includes, but is not limited to, specific novel heterocyclic compounds and salts thereof (particularly pharmaceutically acceptable salts), pharmaceutical compositions containing them as active ingredients, and uses thereof. The present disclosure includes all that is disclosed in the present specification and that can be recognized by a person skilled in the art.
[0015] Certain novel heterocyclic compounds encompassed by the present disclosure have the formula (I):
[0016] (In the formula, R 1 , R 2 are each independently -O - , -OR 4 , or -NR 4Na R 4Nb indicates, R 3represents hydrogen or alkyl, R 4 , R 4Na , and R 4Nb each independently represents hydrogen, or an alkyl, alkenyl, alkadienyl, or alkynyl group which may have 1 to 3 substituents, and R 4 , R 4Na , and R 4Nb The alkyl represented by is a methylene group (-CH 2 -) is -O-, -S-, -CO-, -NH-, -SiR sia R sib - or -(CO)O- may be substituted, and R sia and R sib are the same or different and represent a hydrogen atom or C 1-6 represents alkyl, 1 and R 2 Both - OR 4 When R indicates 1 and R 2 may be the same or different, and 1 and R 2 Both are -NR 4Na R 4Nb When R indicates 1 and R 2 may be the same or different.) It is a heterocyclic compound represented by the following formula: sia and R sib are the same or different and represent a hydrogen atom or C 1-6 Indicates alkyl.
[0017] In this specification, the compound represented by formula (I) is also referred to as "compound (I)." In this specification, examples of "alkenyl" include straight-chain or branched-chain alkenyl (C 1-18 alkenyl), and C 1-12 Alkenyl is more preferred, and C 1-8 Alkenyl, or C 1-6Alkenyl is more preferred. Among the stereoisomers based on the carbon-carbon double bond, alkenyl includes both cis and trans isomers. In the present specification, examples of "alkadienyl" include linear or branched alkadienyl having 1 to 18 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) carbon atoms (C 1-18 alkadienyl), and C 1-12 Alkadienyl is more preferred, and C 1-8 Alkadienyl, or C 1-6 Alkadienyl is more preferred. Among the stereoisomers based on the carbon-carbon double bond, alkadienyl includes both cis and trans isomers. That is, it includes any of the structures (cis, cis), (cis, trans), (trans, cis), or (trans, trans), in the order of the carbon-carbon double bond from the terminal side of the alkadienyl. In the present specification, examples of "alkynyl" include straight-chain or branched-chain alkynyl (C 1-18 alkynyl), and C 1-12 Alkynyl is more preferred, and C 1-8 Alkynyl, or C 1-6 Alkynyl is more preferred. 4 , R 4Na , or R 4Nb represents alkenyl, alkadienyl, or alkynyl, the alkenyl may have one or more (e.g., 1 to 3, preferably 1) substituent groups, the alkadienyl may have one or more (e.g., 1 to 3, preferably 1) substituent groups, and the alkynyl may have one or more (e.g., 1 to 3, preferably 1) substituent groups. Examples of these substituents include halogen, hydroxy, lower alkyl, and lower alkoxy.
[0018] As used herein, examples of "alkyl" include straight or branched chain alkyls (C 1-24 alkyl), and C 1-18 Alkyl is more preferred, and C 1-16 Alkyl, C 1-12 Alkyl, C 1-8 Alkyl, or C 1-6 More preferred examples include alkyl. More specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, heptyl, octyl, nonyl, decyl, and tetradecyl. 4 , R 4Na , and R 4Nb The alkyl represented by is a methylene group (-CH 2 -) is -O-, -S-, -CO-, -NH-, -SiR sia R sib - or -(CO)O- are included. sia and R sib are the same or different and represent a hydrogen atom or C 1-6 In other words, in this specification, R 4 , R 4Na , and R 4Nb The alkyl represented by R includes alkyl having the above-mentioned alternative structure and alkyl not having the above-mentioned alternative structure. 4 , R 4Na , and R 4Nb Unless otherwise specified, alkyls other than the alkyl represented by are alkyls without the above-mentioned alternative structure. In the alkyls with the above-mentioned alternative structure, the number of substituted methylene groups varies depending on the number of carbon atoms in the alkyl before substitution, but is preferably 1 to 8 (1, 2, 3, 4, 5, 6, 7, or 8), more preferably 1 to 6, and even more preferably 1 to 5 or 1 to 4.
[0019] R 1 and R2 are both -OR 4 or R 1 Ga-O - With R 2 Ga-OR 4 Or NR 4Na R 4Nb It is preferable that:
[0020] R 3 When represents alkyl, it is particularly preferably a lower alkyl, more particularly preferably C 1-4 Alkyl is preferred, and methyl or ethyl is more preferred.
[0021] In this specification, the term "lower" used in a substituent having a carbon chain means having 1 to 6 (1, 2, 3, 4, 5, or 6) carbon atoms.
[0022] R 4 , R 4Na , or R 4Nb When represents alkyl, specifically, C 1-24 Alkyl is preferred, C 1-18 Alkyl is more preferred. As described above, the alkyl may have the alternative structure (some methylene groups (-CH 2 -) is -O-, -S-, -CO-, -NH-, -SiR sia R sib As described above, the number of methylene groups to be substituted depends on the number of carbon atoms in the alkyl before substitution, but is preferably 1 to 8 (1, 2, 3, 4, 5, 6, 7, or 8), more preferably 1 to 6, and even more preferably 1 to 5 or 1 to 4. R 1 , R 2 Each independently represents -OR 4 or -NR 4Na R 4Nb In this case, the oxygen atom side (in other words, -OR 4 or -NR 4Na R 4NbWhen the phosphorus atom side to which - is bonded is indicated by *, the -(CO)O- may be either *-(CO)O- or *-O(CO)-. In addition, when multiple methylene groups are substituted, the structures after each substitution (i.e., -O-, -S-, -CO-, -NH-, -SiR sia R sib -, or -(CO)O-) may be the same or different.
[0023] For example, -(CH 2 ) 2 -O-(CH 2 ) 2 -O-CH 3 is -(CH 2 ) 6 -CH 3 is an example of a group in which two methylene groups are replaced by —O—. 2 —(CO)O—CH 2 -CH 3 is -(CH 2 ) 3 -CH 3 is an example of a group in which one methylene group is replaced by *-(CO)O-. 2 ) 3 —O(CO)—CH 3 is -(CH 2 ) 4 -CH 3 is an example of a group in which one methylene group is replaced by *-O(CO)-.
[0024] Also, R 4 , R 4Na , or R 4Nb When represents an alkyl, the alkyl may have one or more (for example, 1 to 3) substituent groups. The substituent groups are attached to the carbon atoms of the alkyl or the nitrogen atoms of —NH— in place of the methylene group, or the methylene group (—CH 2 When the underlined portion of —H is replaced, it is bonded to one side of the replacement structure in place of hydrogen (that is, the substituent is particularly C1 This is expressed as -O-R C1 , -S-RC1 , -CO-R C1 , -NH-R C1 , -SiR sia R sib -R C1 , or -(CO)O-R C1 , or —O(CO)—R C1 (structure of the element)
[0025] Examples of the substituent bonded to the carbon atom of the alkyl include halogen, hydroxy, alkyl (preferably lower alkyl), alkoxy (preferably lower alkoxy), cycloalkyl group, carboxy, alkylaminocarbonyl (preferably lower alkylaminocarbonyl), phenyl or benzyl which may have a substituent, and heterocyclic group which may have a substituent (a group having a structure in which one hydrogen atom bonded to an atom constituting the heterocyclic ring is removed from a heterocyclic ring which may have a substituent).
[0026] In this specification, examples of "halogen" include fluorine, chlorine, bromine and iodine (F, Cl, Br, I), preferably fluorine, chlorine or bromine.
[0027] In this specification, examples of "alkylene" include linear or branched alkylene groups having 1 to 20 carbon atoms. More specific examples include methylene, ethylene, trimethylene, tetramethylene, hexamethylene, heptamethylene, octamethylene, decamethylene, undecamethylene, dodecamethylene, 1-methylethylene, 2-ethyltrimethylene, 1-methylheptamethylene, 2-methylheptamethylene, 1-butylhexamethylene, 2-methyl-5-ethylheptamethylene, 2,3,6-trimethylheptamethylene, and 6-ethyldecamethylene.
[0028] As used herein, examples of "alkoxy" include straight or branched chain alkoxy having 1 to 6 carbon atoms (C 1-6Specific examples thereof include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, isohexyloxy, and 3-methylpentyloxy.
[0029] As used herein, examples of "cycloalkyl" include cyclic alkyls having 3 to 7 (3, 4, 5, 6, or 7) carbon atoms (C 3-7 Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. A cycloalkyl group is a group having a structure in which one hydrogen atom bonded to a carbon atom constituting the cycloalkyl is removed.
[0030] As used herein, examples of "heterocycles" include saturated or unsaturated monocyclic or polycyclic heterocycles containing 1 to 5 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur as ring-constituting atoms, such as saturated or unsaturated 3- to 15-membered, preferably 5- to 10-membered, monocyclic, bicyclic, or tricyclic heterocycles. Specific examples include furan, tetrahydropyran, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, pyrrole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrolidine, imidazolidine, thiophene, piperidine, piperazine, oxazole, isoxazole, oxadiazole, morpholine, indole, indazole, benzimidazole, and quinoline. A heterocyclic group is a group having a structure in which one hydrogen atom bonded to an atom constituting the heterocycle is removed from the heterocycle.
[0031] In the present specification, examples of the "lower alkylaminocarbonyl group" include a methylaminocarbonyl group, a dimethylaminocarbonyl group, an ethylaminocarbonyl group, a propylaminocarbonyl group, an isopropylaminocarbonyl group, and the like.
[0032] Examples of the substituent in the optionally substituted phenyl or benzyl, or the optionally substituted heterocyclic group include R4 In addition, halogen, hydroxy, or halogen, hydroxy, oxo, or C 1-6 C optionally substituted with alkoxy 1-6 C optionally substituted with alkyl, halogen, hydroxy or oxo 1-6 Preferred examples include alkoxy, etc. Furthermore, the number of substituents in the optionally substituted hephenyl or benzyl, or the optionally substituted heterocyclic group may be, for example, 1, 2, or 3.
[0033] Among compounds (I), R 1 But, -O - indicates R 2 But, -OR 4 or -NR 4Na R 4Nb indicates R 3 is preferably hydrogen or methyl. In this case, R 4 or -NR 4Na R 4Nb is more preferably, for example, a group described below. (R 4 : Preferred example 1) R 4 is R 4a1 , R 4a2 , or R 4a3 Indicates. 4a1 is -C n H 2n+1 , -C n H 2n-1 , -C n H 2n-3 , -C n H 2n —OH, —C n H 2n-2 -OH (the -C n H 2n-2 - more preferably has one carbon-carbon double bond therein), or -C n H 2n-4 -OH, (the -C n H 2n-4It is more preferable that the -C has two carbon-carbon double bonds or one carbon-carbon triple bond.) (In the above formula, n represents 1 to 24. n is not limited, but may be, for example, 1 to 18, 1 to 12, 1 to 10, or 1 to 6. However, -C n H 2n-1 So n is 2 or more, -C n H 2n-3 So n is 2 or more, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 -n is 2 or more.) R 4a2 is -CHX 1 X 2 -C n-1 H 2n-2 -CHX 1 X 2 -C n-1 H 2n-4 -CHX 1 X 2 (The relevant -C n-1 H 2n-4 - more preferably has one carbon-carbon double bond therein), or -C n-1 H 2n-6 -CHX 1 X 2 , (the -C n-1 H 2n-6 It is more preferable that the -C has two carbon-carbon double bonds or one carbon-carbon triple bond.) (In the above formula, n represents 2 to 24. n is not limited, but may be, for example, 2 to 18, 2 to 12, 2 to 10, or 2 to 6. However, -C n-1 H 2n-6 -n is 3 or more.
[0034] X 1 and X 2 are the same or different and represent a hydrogen atom or a halogen (F, Cl, Br, or I). However, it is preferable that at least one of them represents a halogen. 4a3 is -C n H 2n -R 4-1 , -C n-1 H 2n-2 -CHR 4-1a R4-1b , -C n H 2n-2 -R 4-1 , or -C n H 2n-4 -R 4-1 (In the above formula, n represents 1 to 24. n is not limited, but may be, for example, 1 to 18, 1 to 12, 1 to 10, or 1 to 6. However, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 -n is 2 or more. 4-1 is C 1-6 Alkoxy, —O-phenyl, or C 1-6 R represents a heterocyclic group optionally substituted with alkyl or halogen. 4-1a and R 4-1b , are the same or different, -C 1-3 Alkylene-C 1-3 or, the same or different, represents an alkoxy; 1-3 Alkyl, or —CH 2 -CO-O-C 1-3 It indicates alkyl. The same applies below. 4-1 When is the heterocyclic group, there is no particular limitation, but suitable examples include the following groups: (R 4 : Preferred example 2) R 4 is R 4b indicates, R 4b Is - (C p H 2p -O) q -C r H 2r -R 4-2 , -(C p H 2p -O) q -C r H 2r-2 -R 4-2 , -(C p H 2p-2 -O) q -C r H 2r -R 4-2 , or -(C p H 2p-2 -O)q -C r H 2r-2 -R 4-2 (In the above formula, p represents 1 to 4, q represents 1 to 4, and r represents 1 to 4. However, C p H 2p-2 So p is 2 or more, C r H 2r-2 In the formula, r is 2 or more. When q is 2 to 4, the 2 to 4 repeating structures representing the number of repetitions represented by q may be the same or different. 4-2 is a hydrogen atom, a hydroxy group, or 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (R represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, each of which may be substituted with 1 to 3 substituents selected from alkoxy and nitro). The same applies below. (R 4 : Preferred example 3) R 4 is -C α H 2α -CO-O-R COO Or -C α H 2α —CO—O—CH 2 -R COO (α represents 1 to 10). COO is a hydrogen atom, 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 Alkyl or C 1-6 Alkoxy or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 R represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. The same applies below. 4 is preferably -C α H 2α -CO-O-R COO -R COO is preferably a hydrogen atom or 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6represents alkyl. (R 4 : Preferred example 4) R 4 is -C β H 2β -O-CO-R OCO (β represents 1 to 10). OCO is R 4a1 , R 4b , or -C α H 2α -CO-O-R COO or -C α H 2α —CO—NH—R COO , -C α H 2α -NH-CO-R COO , or -C α H 2α -NH-CO-OR COO or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 It represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. The same applies below. (R 4 : Preferred example 5) R 4 But, -C γ H 2γ -O-CO-O-R OCOO (γ represents 1 to 10). OCOO is a hydrogen atom, R 4a1 , R 4b , or -C α H 2α -CO-O-R COO or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 It represents a cycloalkyl group, phenyl, benzyl, or heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. The same applies below. (NR 4Na R 4Nb : Preferred example i) R 4Na and R 4Nb are the same or different, and each is 1 to 3 C1-6 C optionally substituted with alkoxy 1-6 It represents alkyl. (NR 4Na R 4Nb : Preferred example ii) R 4Na is a hydrogen atom, and R 4Nb is 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 represents alkyl or -C α H 2α -CO-O-R COO , or -C α H 2α —CO—NH—R COO The symbols used in the description of the above preferred embodiments may be the same or different. For example, -R COO is explained in the above-mentioned preferred example 3 and also described in preferred examples 4 and 5, and -R COO may be the same or different within the scope of the above description. 1 and R 2 But, R 1 Ga-O - With R 2 Ga-OR 4 Or NR 4Na R 4Nb When 2 Preferred examples of R are shown in the table below. 2 The phosphorus atom bond side is indicated with an asterisk (*). When optical isomers exist in the structural formula in the table, all isomers are included.
[0035] In a more preferred embodiment, compound (I) is represented by the following formula (II):
[0036] (In the formula, R 3 and R 4is the same as above). In this specification, among compounds (I), a compound represented by formula (II) is also particularly referred to as "compound (II)". Compound (II) is a compound represented by formula (I) above, where R 1 Ga-O - With R 2 Ga-OR 4 It is a compound having the structure:
[0037] A preferred embodiment of compound (II) is further described below. However, the above description also includes the description of compound (II), and compound (II) is not limited to the following description. 4 Specifically, hydrogen or C optionally having 1 to 3 substituents is 1-18 Examples of alkyl include:
[0038] The substituents are each independently halogen, hydroxy, lower alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , -(CO)NR 7 R 8 , —O(CO)R 9 , -O(CO)OR 10 , -O(CO)-(CR 11 R 12 ) n -(CO)OR 13 , C 3-7 represents a cycloalkyl or a heterocyclic group which may have a substituent. 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 alkyl, a heterocyclic group which may have a substituent, or C 3-7 It represents cycloalkyl. 7 and R 8 each independently represents a hydrogen atom or a lower alkyl in which one or two carbon atoms may be replaced by an oxygen atom or a nitrogen atom; R7 and R 8 may be bonded to form a ring. 11 and R 12 are independently, and R 11 When there are multiple R 12 When a plurality of groups are present, each group independently represents a hydrogen atom, C 1-16 Alkyl, or C 3-7 The term "cycloalkyl" refers to a cycloalkyl group. In addition, n represents an integer of 1 to 10 (1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). In addition, the term "a carbon atom may be replaced by an oxygen atom or a nitrogen atom" in the context of an alkyl group means that "a methylene group (-CH 2 -) may be replaced by -O- or -NH-. In addition, although not particularly limited, examples of the heterocyclic group that may have a substituent include the above-mentioned R 4-1 is C 1-6 Examples of the heterocyclic group that may be substituted with alkyl or halogen include the groups described above. 7 and R 8 When they are bonded to form a ring, -NR 7 R 8 For example, the above-mentioned R 4-1 is C 1-6 Among the groups described as heterocyclic groups which may be substituted with alkyl or halogen, groups having a structure in which one hydrogen atom bonded to a nitrogen atom is removed can be mentioned. 4 More preferably, hydrogen or C optionally having one substituent is 1-8 The substituents are each independently hydroxy, lower alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , —O(CO)R 9 , -O(CO)OR 10 , -O(CO)-A-(CO)OR 13 , or two Cs1-6 The morpholinyl group may have an alkyl group. 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 alkyl, a heterocyclic group which may have a substituent, or C 3-7 A represents cycloalkyl. 1-6 represents alkylene. n is the same as above. R 4 As the alkyl group, hydrogen or C optionally having one substituent is even more preferable. 1-8 The substituents may each independently be hydroxy, C 1-6 Alkoxy, —O—(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , —O(CO)R 9 , -O(CO)-A-(CO)OR 13 , or two Cs 1-6 represents a heterocyclic group optionally having alkyl groups. 5 is C 1-6 Alkyl, R 5a is C 1-6 Alkyl, R 6 is C 1-6 Alkyl, R 9 is C 1-16 Alkyl, R 13 is C 1-6 Alkyl or C 1-6 A represents a pyridyl group which may have an alkyl group. 1-6 represents alkylene, and n is the same as above.
[0039] R 4 Also, hydrogen or -(AY) m -R 14 Here, A is C 1-18 represents alkylene. Y represents a bond, —O—, —(CO)O—, or —(CO)NH—. R14 is hydrogen, halogen, C 1-18 R represents an alkyl, hydroxy, cycloalkyl, or heterocyclic group, and m represents an integer of 0 to 5 (0, 1, 2, 3, 4, or 5). 1 , R 2 Each independently represents -OR 4 In this case, the oxygen atom side (in other words, -OR 4 is bonded to) is indicated by *, the -(CO)O- may be either *-(CO)O- or *-O(CO)-, and the -(CO)NH- may be either *-(CO)NH- or *-NH(CO)-. More specific preferred examples of compound (I) are shown in the table below.
[0040] In one embodiment, diseases that can be prevented and / or treated by compound (I) or a salt thereof include, for example, the following central nervous system diseases: schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, Sleep disorders, adjustment disorders, substance-related disorders, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment, cognitive impairment associated with neurodegenerative diseases, cognitive impairment due to neurodegenerative diseases, cognitive impairment in schizophrenia, cognitive impairment due to treatment-resistant, intractable or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia and borderline personality disorder.
[0041] [General Production Method] Compound (I) can be produced, for example, by the general production method shown below, but is not limited thereto.
[0042] The starting compounds may be commercially available or may be synthesized according to known methods or methods equivalent thereto.
[0043] The solvent, acid, base, protecting group and leaving group that may be appropriately used in the production of compound (I) are not particularly limited, as long as they are commonly used in the field of organic synthetic chemistry.
[0044] In the production of compound (I), the product can be used in the next reaction either as the reaction mixture or as a crude product, or it can be isolated from the reaction mixture in a conventional manner and easily purified by conventional separation means, such as filtration, extraction, concentration, evaporation, crystallization, recrystallization, reprecipitation, distillation, chromatography, and optical resolution.
[0045] In the production of compound (I), when an alkylation reaction, hydrolysis reaction, amination reaction, esterification reaction, amidation reaction, etherification reaction, oxidation reaction, reduction reaction, etc. is carried out, these reactions can be carried out according to known methods.
[0046] These commonly used various reagents and methods are described, for example, in Organic Functional Group Preparations, 2nd Edition, Academic Press, Inc., 1989; Comprehensive Organic Transformations, VCH Publishers Inc., 1990; , published in 1989 by P. G. M. Wuts; T. W. Greene, "Greene's Protective Groups in Organic Synthesis" (4th edition, 2006); John Wiley & Sons; New York, 1991, etc.
[0047] In the general production method of compound (I), the starting compounds, intermediate compounds, and compound (I) may be in the form of salts, and the target compounds obtained in each reaction may also form salts. When each compound is a free compound, it can be converted into the target salt by a known method, and when the compound is a salt, it can be converted into the free form or another target salt by a known method.
[0048] Hereinafter, the method for producing compound (II) will be particularly described. The method for producing compound (II) is a specific example of the method for producing compound (I). Those skilled in the art will understand that compound (I) can be produced by performing similar operations based on this specific example. Those skilled in the art will also understand that compound (I) can be produced based on the production methods described in the examples, methods known in the art, or methods that can be easily derived from known methods.
[0049] Compound (II) can be produced, for example, by the production method shown below. The production methods shown below are illustrative and are not limited to these. In the following reaction scheme, each raw material compound may form a salt as long as it does not inhibit the reaction, and as such a salt, the salts exemplified as salts of compound (II) are used.
[0050] Unless a specific production method is described, commercially available starting compounds may be used, or compounds produced by known methods or methods equivalent thereto may be used. The solvents, acids, bases, protecting groups, and leaving groups appropriately used in the production of compound (II) are not particularly limited as long as they are commonly used in the field of organic synthetic chemistry.
[0051] In the production of compound (II), the product can be used in the next reaction either as the reaction mixture or as a crude product, or it can be isolated from the reaction mixture in a conventional manner and easily purified by conventional separation means, such as filtration, extraction, concentration, evaporation, crystallization, recrystallization, reprecipitation, distillation, chromatography, and optical resolution.
[0052] More specifically, compound (II) can be synthesized, for example, by the following methods classified into Step A and Step B.
[0053] Step A: Phosphoric Acid Coupling Reaction
[0054] In the above formula, LG represents a leaving group, and R 15 represents an alkyl group which may have 1 to 3 substituents, and some of the carbon atoms of the alkyl group may be replaced by -O- and / or -(CO)O-. The other symbols are the same as those described above. 15 The alkyl represented by R 4 The explanation about R applies. 4 and R 15 and may be the same or different, and are preferably different. 15 More preferably, represents optionally substituted straight-chain or branched-chain alkyl.
[0055] Compound (II-1) can be obtained by reacting compound (1) with compound (2) in an inert solvent in the presence or absence of a base depending on the reaction conditions (Step A-1). Compound (1) is brexpiprazole.
[0056] Compound (1) can be produced according to the method described in Patent Document 1 (JP 2006-316052 A), and can be used in free form or in salt form. Examples of salt forms of compound (1) include inorganic acid salts such as hydrochloride, sulfate, phosphate, hydrobromide, hydroiodide, and nitrate; organic acid salts such as formate, propionate, oxalate, carbonate, picrate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, acetate, citrate, tartrate, malonate, succinate, maleate, fumarate, malate, and lactate; and amino acid salts such as aspartate and glutamate.
[0057] Examples of the leaving group include a halogen atom (e.g., chlorine, bromine, iodine), an alkylsulfonyloxy group (e.g., methylsulfonyloxy, ethylsulfonyloxy, trifluoromethylsulfonyloxy), an arylsulfonyloxy group (e.g., benzenesulfonyloxy, p-toluenesulfonyloxy, 2,4,6-trimethylbenzenesulfonyloxy, 2-nitrobenzenesulfonyloxy, 4-nitrobenzenesulfonyloxy), etc. Examples of the inert solvent include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, Et 2 ether solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and preferably halogenated hydrocarbon solvents such as DCM, or aprotic polar solvents such as MeCN.
[0058] As the base, for example, a wide variety of known inorganic and organic bases can be used. Examples of inorganic bases include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3 , Cs 2 CO 3 Examples of the organic base include trialkylamines (e.g., trimethylamine, TEA, DIPEA), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, DBU, and the like. When these bases are liquid, they can also be used as solvents. These bases can be used alone or in combination of two or more. The amount of the base used is usually 0.1 to 10 mol, preferably 0.1 to 5 mol, per 1 mol of compound (1).
[0059] The reaction conditions are not particularly limited, and the reaction can generally proceed under cooling, room temperature, or heating. Preferably, the reaction is carried out at a temperature of room temperature to 100°C for 30 minutes to 350 hours, more preferably 1 hour to 200 hours, and particularly preferably 1 hour to 48 hours. Compound (II) can be obtained by reacting compound (II-1) with an alkali metal halide in an inert solvent under acidic or basic conditions (Step A-2), without any particular limitations on the reaction conditions. Examples of inert solvents include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, and Et 2ether-based solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon-based solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon-based solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and preferred are halogenated hydrocarbon-based solvents such as DCM; aprotic polar solvents such as MeCN; or ketone-based solvents such as acetone.
[0060] As the base, for example, a wide variety of known inorganic and organic bases can be used. Examples of inorganic bases include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3 , Cs 2 CO 3Examples of the organic base include trialkylamines (e.g., trimethylamine, TEA, DIPEA), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, DBU, and the like. When these bases are liquid, they can also be used as solvents. These bases can be used alone or in combination of two or more. The amount of the base used is usually 0.1 to 10 mol, preferably 0.1 to 5 mol, per 1 mol of compound (II-1). Examples of the acid include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, and phosphoric acid; and organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, phthalic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid, and 10-camphorsulfonic acid. Two or more of these may be mixed in an appropriate ratio. The amount of the acid used is usually 1 molar equivalent to an excess amount relative to compound (II-1). Examples of the alkali metal halide include LiI, NaI, and KI. The amount of the alkali metal halide used is usually 1 molar equivalent to an excess amount relative to compound (II-1).
[0061] The reaction conditions are not particularly limited, and the reaction can generally proceed under cooling, room temperature, or heating. Preferably, the reaction is carried out at a temperature of room temperature to 100° C. for 0.5 to 350 hours.
[0062] Step B: Protection-Deprotection
[0063] (wherein PG represents a protecting group for a hydroxy group, -OR 16 is an alkoxy group or —O -The other symbols are the same as above. Compound (1) may be converted into compound (3) protected with an appropriate protecting group (Step B-1), and then subjected to the phosphoric acid coupling reaction (Step A). The protecting group may then be deprotected (Step B-2) to synthesize the final product, compound (II) (Step B). Note that, when performing Step A here, it is also possible to stop at Step A-1 (i.e., react compound (3) with compound (2) to obtain a compound (-OR 16 represents an alkoxy group), or thereafter, Step A-2 is carried out to obtain a compound (II) (-OR 16 Ga-O - A compound (4)) having the formula:
[0064] Step B-1: Protection Reaction Examples of the protecting group (-OPG) for the hydroxy group are not particularly limited as long as they are protecting groups used in the field of organic synthetic chemistry, and include, for example, ethers (e.g., methyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylthiomethyl, tetrahydropyranyl, phenacyl, cyclopropylmethyl, allyl, prenyl, propargyl, t-butyl, benzyl, 4-(dimethylamino)carbonylbenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl, 4-picolyl); silyl ethers (e.g., trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl); phenylsilyl, triisopropylsilyl); esters (e.g., formate, acetate, levulinate, pivaloate, benzoate, 9-fluorenecarboxylate); carbonates (e.g., methyl, t-butyl, isopropyl, allyl, 4-methylsulfinylbenzyl, 2,2,2-trichloroethyl, vinyl, benzyl); arylcarbamate (e.g., phenylcarbamate); phosphinates (e.g., dimethylphosphinyl, dimethylphosphinothioyl); sulfonates (e.g., methanesulfonate, trifluoromethanesulfonate, toluenesulfonate, benzylsulfonate). Preferred examples of the protecting group include ethers.
[0065] For example, in the protection reaction, compound (1) can be reacted in an inert solvent in the presence of a base to give compound (3).
[0066] As the base, for example, a known inorganic base can be used. Examples of the inorganic base include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3 , Cs 2 CO 3 Examples of the base include lower alkali metal alkoxides (e.g., sodium methoxide, sodium ethoxide, etc.), alkali metal hydrides (e.g., NaH, KH, etc.), and silver carbonate. The amount of the base used is usually 1 molar equivalent to an excess amount relative to compound (1). Examples of the inert solvent include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, Et 2 Examples of the solvent include ether solvents such as dimethyl ether (DMF), diisopropyl ether, cyclopentyl methyl ether, and diglyme; ester solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and two or more of these may be mixed and used in an appropriate ratio. Preferred are ether solvents, such as cyclopentyl methyl ether.
[0067] The reaction temperature is usually −80 to 150° C. The reaction time is usually 0.1 to 200 hours.
[0068] Step B-2: Deprotection Reaction The deprotection reaction of compound (4) may be carried out using a known reaction depending on the type of protecting group. For example, the deprotection reaction can be carried out by deprotecting compound (4) in an inert solvent or without a solvent, in the presence or absence of an acid, to give compound (II).
[0069] Examples of the acid include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, and phosphoric acid; and organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, phthalic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid, and 10-camphorsulfonic acid. Two or more of these may be mixed in an appropriate ratio. The amount of the acid used is usually 1 molar equivalent to an excess amount relative to the intermediate (4). Examples of the inert solvent include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, Et 2 ether-based solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF and DMSO; hydrocarbon-based solvents such as n-pentane, n-hexane, n-heptane and cyclohexane; halogenated hydrocarbon-based solvents such as chloroform, DCE and DCM; or other organic solvents; or mixed solvents thereof, and two or more of these may be mixed and used in an appropriate ratio.
[0070] The reaction temperature is usually −80 to 150° C. The reaction time is usually 0.1 to 200 hours. 4 Each compound (II) can also be synthesized by a substitution reaction or a condensation reaction using a compound in which is a hydrogen atom (represented as compound (5) in the following formula). Examples are shown below.
[0071] Step C-1: Substitution reaction In the above formula, LG represents a leaving group, and R 4 is the same as above (except for a hydrogen atom).
[0072] Compound (5) is reacted with R 4 -LG to obtain compound (II) (Step C-1: substitution reaction).
[0073] Examples of the leaving group include halogen atoms (e.g., chlorine, bromine, iodine), alkylsulfonyloxy groups (e.g., methylsulfonyloxy, ethylsulfonyloxy, trifluoromethylsulfonyloxy), arylsulfonyloxy groups (e.g., benzenesulfonyloxy, p-toluenesulfonyloxy, 2,4,6-trimethylbenzenesulfonyloxy, 2-nitrobenzenesulfonyloxy, 4-nitrobenzenesulfonyloxy) and the like.
[0074] Examples of inert solvents include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, and Et 2 ether solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and preferred are aprotic polar solvents such as MeCN; or ketone solvents such as acetone; or mixed solvents thereof with water.
[0075] As the base, for example, a wide variety of known inorganic and organic bases can be used. Examples of inorganic bases include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3, Cs 2 CO 3 Examples of the organic base include trialkylamines (e.g., trimethylamine, TEA, DIPEA), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, DBU, etc. Furthermore, when these bases are liquid, they can also be used as solvents. These bases can be used alone or in combination of two or more.
[0076] The amount of the base used is usually 1 molar equivalent to an excess amount per mole of compound (5) to be reacted.
[0077] The reaction conditions are not particularly limited, and the reaction temperature is usually −80° C. to 150° C. The reaction time is usually 0.1 to 200 hours.
[0078] Steps C-2 and C-2': Condensation reaction In the above formula, R 4 is the same as above (except for a hydrogen atom).
[0079] For example, compound (5) can be reacted with an alcohol (R 4 Compound (II) can be obtained by reacting the alcohol with an amine (HNR 4Na R 4Nb ) by using R 1 Ga-O - With R 2 NR 4Na R 4Nb It is also possible to obtain compound (II') represented by the formula (Step C-2': condensation reaction).
[0080] Examples of inert solvents include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, and Et 2 ether solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and preferred are halogenated hydrocarbon solvents such as DCM; aprotic polar solvents such as MeCN and DMF; or ketone solvents such as acetone; or mixed solvents thereof with water.
[0081] As the base, for example, a wide variety of known inorganic and organic bases can be used. Examples of inorganic bases include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3 , Cs 2 CO 3 Examples of the organic base include trialkylamines (e.g., trimethylamine, TEA, DIPEA), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, DBU, etc. Furthermore, when these bases are liquid, they can also be used as solvents. These bases can be used alone or in combination of two or more.
[0082] The amount of the base used is usually 1 molar equivalent to an excess amount per mole of compound (5) to be reacted.
[0083] As the condensing agent, a wide variety of known condensing agents can be used, for example, 3-ethyl-1-(3-dimethylaminopropyl)carbodiimide (WSC) or its HCl salt; 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide; Hexafluorophosphate (HATU); 1-(chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N,N'-carbonylbis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphites; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphorus chloride) 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide inner salt; benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagents prepared by reacting DMF with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, or the like; and the like.
[0084] The reaction conditions are not particularly limited, and the reaction temperature is usually -80°C to 150°C. The reaction time is usually 0.1 to 200 hours. Furthermore, compound (5) can be used to synthesize each compound (II) by an acylation reaction. This acylation reaction can be considered as one form of the above C-1 (substitution reaction). An example is shown below.
[0085] Step C-3: Acylation reaction In the above formula, R 17 , R 18 is, for example, an alkyl group which may have 1 to 3 substituents (e.g., C 1-18 R is preferably an alkyl group. 17 , R 18 may be the same or different.
[0086] For example, compound (II) can be obtained by reacting compound (5) with an acylating agent such as a carboxylic acid anhydride in an inert solvent or without a solvent in the presence of a base depending on the reaction conditions (Step C-3: acylation reaction).
[0087] Examples of inert solvents include water; alcoholic solvents such as MeOH, EtOH, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; THF, dioxane, and Et 2 ether-based solvents such as AcOMe and AcOEt; aprotic polar solvents such as MeCN, DMF, and DMSO; hydrocarbon-based solvents such as n-pentane, n-hexane, n-heptane, and cyclohexane; halogenated hydrocarbon-based solvents such as chloroform, DCE, and DCM; or other organic solvents; or mixed solvents thereof, and preferred are halogenated hydrocarbon-based solvents such as DCM; aprotic polar solvents such as MeCN and DMF; or ketone-based solvents such as acetone.
[0088] As the base, for example, a wide variety of known inorganic and organic bases can be used. Examples of inorganic bases include alkali metals (e.g., sodium, potassium, etc.), alkali metal hydrogen carbonates (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., LiOH, NaOH, KOH, etc.), alkali metal carbonates (e.g., Li 2 CO 3 , Na 2 CO 3 , K. 2 CO 3, Cs 2 CO 3 Examples of the organic base include trialkylamines (e.g., trimethylamine, TEA, DIPEA), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, DBU, etc. Furthermore, when these bases are liquid, they can also be used as solvents. These bases can be used alone or in combination of two or more.
[0089] The amount of the base used is usually 1 molar equivalent to an excess amount per mole of compound (5) to be reacted.
[0090] The reaction conditions are not particularly limited, and the reaction temperature is usually −80° C. to 150° C. The reaction time is usually 0.1 to 200 hours.
[0091] In this specification, compound (I), starting compounds, and intermediate compounds may be used in the form of chemically acceptable geometric isomers, stereoisomers, optical isomers, and tautomers. Various isomers can be separated by a general optical resolution method, or can be produced from the corresponding optically active starting compounds.
[0092] In this specification, compound (I), starting compounds, and intermediate compounds may also be in the form of salts, and the target compounds obtained in each reaction may also form salts. When the compounds obtained in each reaction are free compounds, they can be converted into the target salts by known methods. When the compounds are salts, they can be converted into the free form or other target salts by known methods. Examples of such salts include the salts exemplified below. As salts, pharmaceutically acceptable salts are preferred, and metal salts (e.g., alkali metal salts, alkaline earth metal salts, zinc salts, etc.) are preferred. In addition, acid addition salts or base addition salts are preferred. Examples of the acid in the acid addition salt include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, and phosphoric acid; organic acids such as formic acid, propionic acid, oxalic acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, acetic acid, citric acid, tartaric acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, and lactic acid; and amino acids such as aspartic acid and glutamic acid. Examples of the base in the base addition salt include metals such as alkali metals (e.g., sodium, potassium, etc.) and alkaline earth metals (e.g., calcium, magnesium, etc.); inorganic bases such as alkali metal carbonates (e.g., lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.), alkali metal hydrogencarbonates (e.g., lithium hydrogencarbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), and alkali metal hydroxides (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, cesium hydroxide, etc.); and organic bases such as methylamine, diethylamine, trimethylamine, triethylamine, N-ethyldiisopropylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, guanidine, pyridine, quinoline, piperidine, imidazole, dimethylaminopyridine, dimethylaniline, picoline, choline, N-methylmorpholine, DBN, DBU, DABCO, etc.; amino acids such as lysine and arginine; and ammonia.
[0093] Compound (I) or a salt thereof can be used in the form of various solvates (particularly hydrates). Compound (I) or a salt thereof can also be used in the form of a crystalline polymorph. Compound (I) or a salt thereof can also be used in the form of a pharmaceutically acceptable co-crystal or co-crystal salt. Here, a co-crystal or a co-crystal salt refers to a crystalline substance composed of two or more unique solids at room temperature, each having different physical properties (e.g., structure, melting point, heat of fusion, etc.). Co-crystals and co-crystal salts can be produced by applying known co-crystallization methods.
[0094] Compound (I) includes compounds in which any one or more atoms of formula (I) are substituted with one or more isotope atoms. Examples of isotope atoms include deuterium ( 2 H), tritium ( 3 H), 13 C. 15 N. 18 O. Compound (I) also includes compounds labeled with various radioactive or non-radioactive isotopes.
[0095] Compound (I) can be used in combination with various therapeutic or preventive agents for diseases that can be treated by compound (I). The combination may be administered simultaneously, or separately, consecutively, or at a desired time interval. The simultaneous administration preparation may be a combined preparation or may be formulated separately.
[0096] Next, a pharmaceutical preparation (hereinafter also referred to as "pharmaceutical composition") containing Compound (I) as an active ingredient will be described.
[0097] The pharmaceutical preparation is prepared by formulating Compound (I) into a conventional pharmaceutical formulation using Compound (I) or a salt thereof and a pharmaceutically acceptable carrier, which may include commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, suspending agents, solubilizers, isotonicity agents, and solvents.
[0098] Such pharmaceutical preparations can be selected from various forms depending on the purpose of treatment, and include, for example, tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections, nasal drops, inhalants, etc., with injections being particularly preferred. Injections include injections for intramuscular administration and injections for subcutaneous administration, with subcutaneous injections being particularly preferred.
[0099] A wide variety of known carriers can be used when forming tablets, including excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, and crystalline cellulose; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, and polyvinylpyrrolidone; and dry starch, sodium alginate, agar powder, laminaran powder, and sodium bicarbonate. disintegrants such as calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose; disintegration inhibitors such as sucrose, stearin, cocoa butter, hydrogenated oil; absorption promoters such as quaternary ammonium bases, sodium lauryl sulfate; humectants such as glycerin, starch; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silicic acid; and lubricants such as purified talc, stearates, boric acid powder, polyethylene glycol.
[0100] Furthermore, the tablets may be coated with conventional tablets as required, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double-layered tablets, or multi-layered tablets.
[0101] A wide range of known carriers can be used when forming the tablets into pills, including excipients such as glucose, lactose, starch, cocoa butter, hardened vegetable oil, kaolin, and talc; binders such as powdered gum arabic, powdered tragacanth, gelatin, and ethanol; and disintegrants such as laminaran and agar.
[0102] As the carrier used for forming into suppositories, a wide variety of known carriers can be used, including, for example, polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc.
[0103] When prepared as an injection, the solution, emulsion, and suspension are preferably sterilized and isotonic with blood. Diluents used in forming these solutions, emulsions, and suspensions can be any known and widely used diluent, such as water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and polyoxyethylene sorbitan fatty acid esters. In this case, the pharmaceutical preparation may contain sufficient amounts of salt, glucose, amino acids, or glycerin to prepare an isotonic solution. It may also contain conventional solubilizers, buffers, soothing agents, and the like, as well as preservatives, stabilizers, antioxidants, solubilizers, pH adjusters, and other pharmaceuticals, as needed.
[0104] Brexpiprazole is known to be useful in alleviating symptoms associated with Alzheimer's disease, such as severe agitation, disruptive behavior, and violent behavior. Rapid-release injectable antipsychotics are known to be useful as treatments for alleviating symptoms in patients with acute schizophrenia and other conditions accompanied by severe agitation, disruptive behavior, and violent behavior. Therefore, an injectable formulation that rapidly releases brexpiprazole into the bloodstream is expected to be useful as a treatment for alleviating symptoms in patients with acute agitation associated with schizophrenia and Alzheimer's disease. A pharmaceutical composition containing compound (1) designed in a preferred injectable form to meet medical needs can be administered subcutaneously or intramuscularly to rapidly deliver a therapeutically effective amount of brexpiprazole into the patient's bloodstream over a short period of time (e.g., several hours) in acute uses, such as agitation, and is expected to rapidly demonstrate its efficacy. An example of a preferred form of injection for acute use is an injection prepared by dissolving compound (1) in water for injection, a biocompatible organic solvent, or a mixture of water for injection and a biocompatible organic solvent, optionally containing an appropriate isotonicity agent, buffer, pH adjuster, solubilizer, etc. Examples of solubilizers include polysorbate 80, polysorbate 60, polyoxyethylene hydrogenated castor oil 60, poloxamer, β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, etc. Examples of isotonicity agents include alkali metal chlorides such as sodium chloride and potassium chloride; sugar alcohols such as mannitol, sorbitol, xylitol, and maltitol; sugars such as glucose, trehalose, and maltose; and glycerin. The composition may not contain an isotonicity agent; however, if an isotonicity agent is contained, the concentration of the isotonicity agent in the composition is preferably such that the osmotic pressure of the solution of the composition becomes isotonic. Although it depends on the type of isotonic agent, for example, in the case of alkali metal chlorides, the concentration is preferably 0.5 to 20 mg / mL, more preferably 2 to 10 mg / mL, and in the case of sugar alcohols and sugars, the concentration is preferably 10 mg / mL to 200 mg / mL, more preferably 20 to 100 mg / mL.Examples of buffering agents include phosphates such as sodium phosphate, sodium dihydrogen phosphate, monosodium hydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate; borates such as sodium borate and potassium borate; citrates such as sodium citrate and disodium citrate; acetates such as sodium acetate and potassium acetate; carbonates such as sodium carbonate and sodium bicarbonate; trishydroxymethylaminomethane (Tris), etc. The concentration of the buffering agent in the composition is, for example, 0.01 to 5.0 mg / mL, and preferably 0.1 to 2 mg / mL.
[0105] The pH adjuster may be either an acidic or basic pH adjuster. Examples of acidic pH adjusters include hydrochloric acid, phosphoric acid, acetic acid, and citric acid. Examples of basic pH adjusters include sodium hydroxide, potassium hydroxide, calcium carbonate, magnesium oxide, and magnesium hydroxide. The pH adjuster is typically added in an appropriate amount depending on the desired pH of the composition. Examples of biocompatible organic solvents include those miscible with water, such as alcohols (e.g., ethanol, propanol, isopropanol, propylene glycol, and glycerin), as well as dimethyl sulfoxide, N-methyl-2-pyrrolidone, polyethylene glycol 300, and polyethylene glycol 400. Treatment of agitation associated with schizophrenia, depression, and Alzheimer's disease is often achieved with once-daily tablets, but medication refusal and agitation can make taking tablets difficult. In such cases, sustained-release injectables (preferably subcutaneous sustained-release injectables) administered every one to several days are considered useful because they ensure reliable drug administration and are convenient. Pharmaceutical compositions containing compound (1) designed in a preferred injectable form tailored to medical needs can be administered subcutaneously or intramuscularly to deliver a therapeutically effective amount of brexpiprazole to the patient's bloodstream over a relatively short period (1 to several days), even in patients who have difficulty taking tablets. This sustained delivery of a therapeutically effective amount of brexpiprazole is expected to produce efficacy over a period of 1 to several days. In the treatment of schizophrenia, long-acting injectables are a useful dosage form for improving therapeutic and preventive effects in patients with poor medication adherence. For a drug to exert its therapeutic effect, it is generally desirable for the blood drug concentration to rapidly reach the therapeutic range and then maintain a certain level. Representative long-acting injectable formulations for the treatment of schizophrenia include aripiprazole and paliperidone palmitate (trade names: Abilify Long-acting Aqueous Suspension Intramuscular Injection and Zeplion Aqueous Suspension Intramuscular Injection). However, due to their poor solubility and slow dissolution after administration, oral agents are often used in combination or the injection interval is shortened to compensate for the initial blood drug concentration.A pharmaceutical composition containing compound (1) designed in the form of a preferred injectable formulation in accordance with medical needs can be administered subcutaneously or intramuscularly to rapidly and continuously deliver a therapeutically effective amount of brexpiprazole into the bloodstream of a patient over a relatively short period (1 to 4 weeks or more), even in patients in whom sufficient therapeutic or preventive effects are not expected due to poor medication adherence, and is therefore expected to improve the therapeutic or preventive effects in such patients.
[0106] A preferred example of the form of a sustained-release injectable formulation for sustained delivery of brexpiprazole over one to several days or one to four weeks or more is a pharmaceutical composition in the form of a suspension containing compound (1), a suspending agent, and a dispersion medium. The concentration of compound (1) in the composition is not particularly limited as long as it is an effective concentration depending on the intended use of the composition. The concentration of compound (1) in the composition is, for example, 50 mg / mL or more, preferably 100 mg / mL or more, more preferably 150 mg / mL or more, and even more preferably 200 mg / mL or 250 mg / mL or more, calculated as brexpiprazole. The upper limit is not particularly limited, but examples include 1000 mg / mL or less, 750 mg / mL or less, or 500 mg / mL or less. For example, the composition can be used in the range of 50 to 1000 mg / mL. The suspending agent contained in the composition is not particularly limited, as long as it is pharmaceutically acceptable and can achieve the desired viscosity. Examples of suspending agents include carboxymethylcellulose and its salts; polyoxyethylene-polyoxypropylene block copolymers such as poloxamers; and polyethylene glycol (also known as "macrogol"). Examples of carboxymethylcellulose salts include metal salts such as alkali metal salts and ammonium salts. Specific examples include sodium carboxymethylcellulose, potassium carboxymethylcellulose, lithium carboxymethylcellulose, ammonium carboxymethylcellulose, and mixtures thereof. In one embodiment, the suspending agent preferably contains carboxymethylcellulose and / or its sodium salt, and sodium carboxymethylcellulose is particularly preferred. The suspending agent may be a single agent or a combination of two or more agents. The concentration of the suspending agent in the composition is, for example, 0.1 mg / mL or more, preferably 0.2 mg / mL or more, and more preferably 0.5 mg / mL or more. The concentration of the suspending agent in the composition is, for example, 100 mg / mL or less, preferably 50 mg / mL or less, and more preferably 25 mg / mL or less. The concentration of the suspending agent in the composition is, for example, 0.1 to 50 mg / mL.
[0107] The dispersion medium contained in the composition is not particularly limited, as long as it is pharmaceutically acceptable and capable of dispersing the active ingredient. The dispersion medium may be a single type or a combination of two or more types. The dispersion medium preferably contains at least water. Examples of such dispersion mediums include water, physiological saline, and a solvent containing water and the biocompatible organic solvent. In a preferred embodiment, the dispersion medium is water, and purified water, sterile purified water, and water for injection are particularly preferred. The composition may further contain optional additives. Such additives are not particularly limited as long as they are pharmaceutically acceptable, and examples include the aforementioned isotonicity agents, buffers, and pH adjusters. The additives may be used alone or in combination. The average particle size of the suspended compound (1) is, for example, 0.1 to 30 μm, preferably 0.5 to 20 μm. This range is preferable in terms of prolonged duration of action. On the other hand, if high blood drug concentrations are desired immediately after administration, the average particle size of the suspended compound (1) is, for example, 500 nm or less, preferably 50 to 500 nm. The average particle size is measured by a laser diffraction scattering method. For example, an SALD-3100 or SALD-2300 (manufacturer: Shimadzu Corporation) can be used to measure the average particle size by the laser diffraction scattering method. The composition is preferably prepared by a wet grinding method. Examples of the wet grinding method include wet ball milling, high-pressure homogenization, high-shear homogenization, and a bead mill (e.g., a Dyno Mill). In addition to the grinding methods, other low- and high-energy mills (e.g., roller mills) can also be used. Other preparation methods include controlled crystallization.
[0108] In one embodiment, the composition can be produced by a method including, for example, Step 1: mixing Compound (1), a suspending agent, and a dispersion medium; Step 2: bead-milling the resulting suspension; and Step 3: removing beads from the resulting suspension. In Step 1, the order of mixing the components is not particularly limited. In one embodiment, Step 1 comprises mixing components other than the active ingredient to obtain a vehicle solution, and mixing the vehicle solution with the active ingredient. In Step 2, the method of bead-milling is not particularly limited. In one embodiment, Step 2 comprises adding beads to the suspension and stirring. Examples of materials for the beads include zirconia, alumina, and glass. The diameter of the beads is, for example, 0.1 to 5 mm, preferably 0.2 to 3 mm. The average particle size of Compound (1) particles obtained by bead-milling can be adjusted appropriately by adjusting the size of the beads, the rotation speed (peripheral speed) during milling, the milling time, etc. In Step 3, the method of removing the beads is not particularly limited. In one embodiment, step 3 involves recovering the composition using a needle (e.g., 22G or smaller) or pipette with a pore size smaller than the beads, or a mesh filter (e.g., 80 μm mesh). Another preferred form of injectable formulation for sustained delivery of brexpiprazole over one to several days or one to four weeks or longer is a pharmaceutical composition comprising a low-viscosity precursor formulation comprising a mixture of compound (1), multiple liquid crystal-forming or gel-forming lipids, and at least one biocompatible organic solvent, which forms or is capable of forming at least one liquid crystal phase structure or lipid gel upon contact with aqueous fluids in vivo. The precursor formulation typically does not contain significant amounts of water before administration and is a low-viscosity liquid or suspension in which multiple liquid crystal-forming or gel-forming lipids are dissolved in a biocompatible organic solvent. The pre-liquid crystal-forming or gel-forming lipid is a type of amphiphilic component, preferably a combination of at least one diacylglycerol and at least one phosphatidylcholine.A low-viscosity solution can be prepared by dissolving the pre-liquid crystal-forming lipid or gel-forming lipid in at least one biocompatible organic solvent, and by incorporating compound (1) in a dissolved or suspended state in these solutions, a precursor formulation, which is a preferred low-viscosity liquid or suspension, can be prepared. Such precursor formulations form a liquid crystal phase structure or a high-viscosity lipid gel upon contact with aqueous fluids in vivo after administration. Generally, the aqueous fluid is a body fluid, particularly extravascular fluid, extracellular / interstitial fluid, or plasma, and the precursor formulation forms a liquid crystal phase structure or a high-viscosity lipid gel upon contact with such fluids (e.g., in vivo fluids).
[0109] A precursor formulation that is a low-viscosity liquid or suspension refers to a liquid or suspension that can be easily administered to a subject, particularly a mixture that can be easily administered using a device consisting of a standard syringe and needle. In a particularly preferred embodiment, the precursor formulation in which compound (1) is dissolved or the medium prior to suspending compound (1) should be a mixture that can pass through a standard sterile filtration membrane, such as a 0.22 μm syringe filter. Typical suitable viscosity ranges are, for example, 0.1 to 5,000 mPa·s, preferably 1 to 1,000 mPa·s, and more preferably 1 to 500 mPa·s, at 20°C. The above viscosity is measured using a rotational rheometer at a shear rate of 9,000 to 10,000 (1 / s) at 20°C. Examples of rotational rheometers include the Discovery Hybrid Rheometer-2 (DHR-2) and the Discovery Hybrid Rheometer-3 (DHR-3) (manufacturer: TA Instruments). After administration to a living body, the precursor formulation may form a liquid crystal structure called lyotropic liquid crystal when the amphiphilic compounds (plural types of liquid crystal-forming lipids or gel-forming lipids) are exposed to an aqueous fluid. Examples of such liquid crystal structures include hexagonal structures in which cylindrical aggregates form a hexagonal crystal system, lamellar structures, inverted hexagonal structures in which water is incorporated into the cylinder with the lipophilic portion facing outward, cubic structures in which spherical micelles form cubic crystals in a water (or oil) continuous phase, and bicontinuous cubic structures in which lipid bilayers are connected three-dimensionally to form a curved surface. The present inventors have discovered that by forming the liquid crystal or lipid gel after administration of the precursor formulation to a living body, the release of compound (1) after administration can be controlled, and the released compound (1) can be converted to brexpiprazole in vivo, thereby enabling sustained delivery of brexpiprazole.
[0110] The formation of a gel or liquid crystal can be confirmed by pouring the precursor formulation into water and observing the formation of a mass. The formation of a liquid crystal can be confirmed by analyzing the resulting mass using small-angle X-ray scattering (SAXS). It is also possible to say that both liquid crystal and gel form (liquid crystalline gel). Diacylglycerol has two nonpolar "tail" groups, which may be the same or different, have the same or different numbers of carbon atoms, and may be independently saturated or unsaturated. Both 1,3-diacylglycerol and 1,2-diacylglycerol can be used. Examples of nonpolar groups include C6-C32 alkyl groups and C6-C32 alkenyl groups, which are typically present as esters of long-chain carboxylic acids. These are often described in terms of the number of carbon atoms and unsaturation in the carbon chain. Thus, CX:Z refers to a hydrocarbon chain with X carbon atoms and Z unsaturation. Examples include, inter alia, caproyl (C6:0), capryloyl (C8:0), capryl (C10:0), lauroyl (C12:0), myristoyl (C14:0), palmitoyl (C16:0), phytanoyl (C16:0), palmitoleoyl (C16:1), stearoyl (C18:0), oleoyl (C18:1), elaidoyl (C18:1), linoleoyl (C18:2), linolenoyl (C18:3), arachidonoyl (C20:4), behenoyl (C22:0), and lignoceroyl (C24:9). Thus, typical non-polar chains are based on fatty acids of natural ester lipids, including caproic, caprylic, capric, lauric, myristic, palmitic, phytanic, palmitoleic, stearic, oleic, elaidic, linoleic, linolenic, arachidonic, behenic, or lignoceric acids, or their corresponding alcohols. Preferred non-polar chains are palmitic, stearic, oleic, and linoleic acids, especially oleic acid.The diacylglycerol is not particularly limited, but is preferably, for example, a diacylglycerol having the same or different nonpolar chains as described above, with glycerol dioleate (GDO) being particularly preferred. Diacylglycerols can be used alone or in combination of two or more. Phosphatidylcholine (PC) is a general term for phospholipids in which choline is linked via a phosphate ester bond as the hydrophilic portion of the glycerophospholipid and two fatty acids are ester-linked to the glycerol backbone as the hydrophobic portion. Due to the large number of fatty acid combinations, there are multiple phospholipids that belong to the phosphatidylcholine family. Suitable phospholipid sources include egg, heart (e.g., bovine heart), brain, liver (e.g., bovine liver), and plant sources, including soybean. While a single PC or a mixture of multiple PCs derived from such sources may be used, soybean PC (SPC), egg-derived PC, or a mixture thereof is preferred, with essentially pure SPC (high-purity SPC) being most preferred. As the liquid crystal-forming lipid or gel-forming lipid, it is preferable to use a combination of at least one diacylglycerol and at least one phosphatidylcholine. In particular, it is preferable to use a combination of one or more of the diacylglycerols specifically mentioned above and one or more of the phosphatidylcholines specifically mentioned above. A particularly preferred combination of liquid crystal-forming lipid or gel-forming lipid is GDO and PC, particularly GDO and soybean PC and / or egg PC.
[0111] Examples of biocompatible organic solvents are preferably those miscible with water, and representative solvents include at least one solvent selected from alcohols, ketones, esters (including lactones), ethers, amides, and sulfoxides. Alcohols are particularly preferred and form a preferred solvent group. Examples of suitable alcohols include ethanol, isopropanol, propylene glycol, glycerin, and glycerol formal, with ethanol being most preferred. Examples of ketones include acetone, n-methylpyrrolidone (NMP), 2-pyrrolidone, and propylene carbonate. Suitable ethers include diethyl ether, glycofurol, diethylene glycol monoethyl ether, dimethylisobarbide, and polyethylene glycol. Suitable esters include ethyl acetate and isopropyl acetate, and dimethyl sulfide is a preferred sulfide solvent. Suitable amides and sulfoxides include dimethylacetamide (DMA) and dimethyl sulfoxide (DMSO), respectively. Biocompatible organic solvents can be used singly or in combination. A preferred combination of low-viscosity precursor formulations containing a mixture of multiple liquid crystal-forming or gel-forming lipids and at least one biocompatible organic solvent is SPC, GDO, and ethanol, with SPC, GDO, ethanol, and DMSO also being suitable. A preferred low-viscosity precursor formulation is prepared by dissolving or suspending compound (1) in a solution containing multiple liquid crystal-forming or gel-forming lipids and at least one biocompatible organic solvent. Another preferred form of injection for sustained delivery of brexpiprazole over one to several days or one to four weeks or longer is microspheres containing compound (1) as an active ingredient. Microspheres generally refer to spherical formulations with particle diameters of several micrometers to several tens of micrometers, and may have an uneven surface. The microspheres of the present disclosure typically contain a carrier such as a base polymer (e.g., a biodegradable polymer).In order to obtain the desired controlled-release characteristics of compound (I), the average particle size of the microspheres of the present disclosure is preferably 5 to 150 μm, more preferably 10 to 120 μm, even more preferably 20 to 100 μm, and more preferably 30 to 85 μm. To obtain the desired controlled-release characteristics, the average particle size can be reduced if a faster absorption rate is required, or increased if a slower absorption rate is required. To obtain the desired controlled-release characteristics of compound (I) and the desired blood drug concentration profile of brexpiprazole, the encapsulation rate of compound (1) in the microspheres of the present disclosure is preferably 80% or higher. To improve the encapsulation rate, the amount of active ingredient charged in the batch formulation can also be increased.
[0112] In the microspheres of the present disclosure, from the viewpoint of obtaining the desired controlled release characteristics of compound (I) and the desired change in blood drug concentration of brexpiprazole over time, the content of compound (I) is preferably 10 to 50% by weight, more preferably 20 to 45% by weight, and even more preferably 30 to 40% by weight. The microspheres of the present disclosure preferably contain a biodegradable polymer as a base polymer. The biodegradable polymer used in the present disclosure may be any polymer that is gradually degraded in vivo to provide the desired sustained-release performance, and examples thereof include homopolymers such as polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer (poly(lactic-co-glycolic acid): PLGA), polycitric acid, polymalic acid, lactic acid-aspartic acid copolymer, lactic acid-hydroxycaproic acid copolymer, glycolic acid-hydroxycaproic acid copolymer, polypropiolactone, polybutyrolactone, polyvalerolactone, polycaprolactone, polytrimethylene carbonate, poly-p-dioxanone, poly-α-cyanoacrylate, poly-β-hydroxybutyric acid, polytrimethylene oxalate, polyorthoester, polyorthocarbonate, polyethylene carbonate, poly-γ-benzyl-L-glutamic acid, poly-L-alanine, polyalginic acid, polycarbonate, polyesteramide, polyamino acid, polyalkylene alkylate, polyethylene glycol, polyurethane, and copolymers thereof. Among these, polylactic acid and lactic acid-glycolic acid copolymers are preferred. These biodegradable polymers may be used alone or in combination of two or more. When polylactic acid or lactic acid-glycolic acid copolymers are used, their molecular weights may be appropriately selected from a wide range, but are typically about 2,000 to 200,000, preferably about 4,000 to 100,000, and more preferably about 10,000 to 70,000. Here, the above-mentioned molecular weights refer to weight-average molecular weights converted into polystyrene weights, measured by gel permeation chromatography (GPC) using polystyrene as the reference material.The lactic acid:glycolic acid (lactide:glycolide) ratio in the lactic acid-glycolic acid copolymer is not particularly limited and may be appropriately selected from a wide range. It is typically about 99:1 to 1:99 molecular ratio, preferably about 85:15 to 50:50 molecular ratio. The polylactic acid may be poly-D-lactic acid, poly-L-lactic acid, or poly-DL-lactic acid, with poly-DL-lactic acid being preferred. The lactic acid-glycolic acid copolymer may be D-lactic acid-glycolic acid copolymer, L-lactic acid-glycolic acid copolymer, or DL-lactic acid-glycolic acid copolymer, with DL-lactic acid-glycolic acid copolymer being preferred. Polylactic acid or lactic acid-glycolic acid copolymer can be produced by known methods, and commercially available products (e.g., Resomer, Lactel (manufactured by Evonik)) can also be used. The microspheres of the present disclosure may contain a non-degradable biocompatible polymer in addition to the biodegradable polymer. The microspheres of the present disclosure may also contain optional additives such as emulsifiers.
[0113] The microspheres of the present disclosure can be produced using the above-mentioned components by methods known in the pharmaceutical field. From the viewpoint of obtaining microspheres with excellent sustained-release properties, fluidity during filling, and syringe permeability during administration, the microspheres of the present disclosure are preferably produced by dissolving or suspending compound (I) or a salt thereof and a biodegradable polymer in an organic solvent, emulsifying the mixture with or without an emulsifier, and then removing the organic solvent. Further steps known in the pharmaceutical field (e.g., filtration and sizing) may also be included. The method for producing the microspheres of the present disclosure is described in more detail below. The method for producing the microspheres of the present disclosure includes the steps of obtaining a solution or suspension containing compound (I) and a biodegradable polymer in an organic solvent; mixing the obtained solution or suspension with water and emulsifying the mixture with or without an emulsifier to obtain an emulsion; and removing the organic solvent from the obtained emulsion. First, compound (I) and a biodegradable polymer are dissolved or suspended in an organic solvent to obtain a uniform solution or suspension. Compound (I) may be dissolved or suspended in the organic solvent. The biodegradable polymer is preferably dissolved in an organic solvent. The organic solvent used in the production of microspheres of the present disclosure is not particularly limited as long as it can dissolve the biodegradable polymer. Examples include halogenated hydrocarbons such as chloroform, dichloroethane, trichloroethane, dichloromethane, and carbon tetrachloride; ethers such as ethyl ether and isopropyl ether; fatty acid esters such as ethyl acetate and butyl acetate; aromatic hydrocarbons such as benzene, toluene, and xylene; alcohols such as ethanol, methanol, isopropanol, and benzyl alcohol; nitriles such as acetonitrile; amides such as dimethylformamide; and water-miscible or water-immiscible organic solvents such as acetone. These organic solvents may be used alone or in combination. Among these, water-immiscible organic solvents, particularly dichloromethane, are preferred. Acids or bases can also be added to these organic solvents. Examples of acids include hydrochloric acid, phosphoric acid, acetic acid, citric acid, formic acid, gluconic acid, lactic acid, oxalic acid, tartaric acid, and oleic acid, with acetic acid being particularly preferred.
[0114] The ratio of compound (I) or a salt thereof to the organic solvent is typically about 0.01 to 30 parts by weight, preferably about 0.1 to 20 parts by weight, and more preferably about 1 to 10 parts by weight, of compound (I) or a salt thereof per 100 parts by weight of the organic solvent. The ratio of the biodegradable polymer to the organic solvent is typically about 0.01 to 30 parts by weight, preferably about 0.1 to 20 parts by weight, and more preferably about 1 to 10 parts by weight, of the biodegradable polymer per 100 parts by weight of the organic solvent. Next, the resulting organic solvent solution or suspension (comprising compound (I), the biodegradable polymer, and the organic solvent) is emulsified. That is, the resulting organic solvent solution is mixed with water (the so-called external phase) to obtain an O / W type emulsion in which the organic solvent solution is uniformly dispersed in water, or the resulting organic solvent suspension is mixed with water (the so-called external phase) to obtain an S (solid) / O / W type emulsion in which the suspension is uniformly dispersed in water. The water used is not particularly limited, but is preferably acceptable in the field of pharmaceutical formulations, such as purified water or water for injection. The ratio of the organic solvent solution or suspension to water is not particularly limited as long as it is a ratio that allows an O / W or S / O / W emulsion of the desired particle size to be obtained, but is typically about 0.001 to 0.2 parts by volume, preferably about 0.005 to 0.1 parts by volume, and more preferably about 0.01 to 0.05 parts by volume of the organic solvent solution or suspension to 1 part by volume of water. In the present disclosure, whether a water-miscible or water-immiscible organic solvent is used, an emulsifier may be used. When a water-miscible organic solvent is used, it is preferable to use an emulsifier. The emulsifier used in the present disclosure may be any that can form an O / W or S / O / W emulsion, preferably a stable O / W or S / O / W emulsion, and examples thereof include anionic surfactants such as sodium oleate, sodium stearate, and sodium lauryl sulfate; nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters and polyoxyethylene castor oil derivatives; polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, and hyaluronic acid. These emulsifiers may be used alone or in combination of two or more.
[0115] The emulsifier may be added to the aqueous phase before emulsification. The amount of emulsifier used is not particularly limited and may be selected from a wide range, but the concentration in the aqueous emulsifier solution is, for example, about 0.0001 to 20% by weight, preferably about 0.001 to 10% by weight, and more preferably about 0.001 to 5% by weight. The method for preparing the O / W type or S / O / W type emulsion is not particularly limited, and any method may be used in which the organic solvent solution or suspension (containing compound (I) or a salt thereof, a biodegradable polymer, and an organic solvent) is dispersed in water as droplets or micelles of an appropriate size. Examples of such preparation methods include a method in which a mixture of the above solution or suspension and water is stirred at an appropriate rotation speed using a homogenizer or the like to micronize the solution or suspension in water to form an O / W or S / O / W emulsion; a method in which a mixture of the above solution or suspension and water is passed through a filter with fine through-holes, such as a ceramic filter, at a constant speed to micronize the solution or suspension to form an O / W or S / O / W emulsion; and a method in which the above solution or suspension is passed through a filter with fine through-holes, such as a ceramic filter, at a constant speed to micronize the solution or suspension, and then mixed with water. If necessary, emulsion formation may be carried out in multiple stages. The desired particle size can be obtained by adjusting the stirring force during emulsion formation. That is, increasing the stirring force during emulsion formation can reduce the particle size. An aqueous suspension of microspheres is obtained by removing the organic solvent from the resulting O / W or S / O / W emulsion. A commonly used method is used to remove the organic solvent. Examples of such methods include heating while stirring with a propeller stirrer or magnetic stirrer, gradually reducing the pressure, or using a rotary evaporator to adjust the degree of vacuum while detaching. The microsphere suspension thus obtained may be washed to remove free Compound (I) adhering to the surface of the microspheres by adding an appropriate solution or solvent, if necessary. Examples of washing solutions or solvents include alkaline solutions such as ethanol and 1N sodium hydroxide solution.After separating the microspheres by centrifugation or filtration, free Compound (I), emulsifier, etc. adhering to the surface of the microspheres are washed several times with distilled water, and if necessary, with an appropriate solution or solvent. Examples of washing solutions or solvents include alkaline solutions such as ethanol or 1N sodium hydroxide solution. If necessary, the separated microspheres are heated and then desorbed under reduced pressure to more completely remove water and solvent from the microspheres. Alternatively, the washed microspheres can be resuspended in water with or without sugars, sugar alcohols, or other additives, and then lyophilized to obtain microsphere powder. The lyophilization conditions are not particularly limited as long as the microspheres can be dried.
[0116] Furthermore, the dried microspheres may be sieved as needed to obtain microspheres having the desired average particle size. The microspheres of the present disclosure, particularly those obtained by the above-described production method, have excellent sustained-release properties. The microspheres of the present disclosure can release Compound (I) or a salt thereof in therapeutic amounts for at least one week, more preferably two, three, or four weeks, and even more preferably six weeks or more. The microspheres of the present disclosure can particularly exhibit the above-described effects when suspended in water for injection to form an aqueous suspension injection. The microspheres of the present disclosure obtained by the above-described production method typically have a spherical shape. The spherical shape of the microspheres of the present disclosure provides good fluidity during filling during production and syringeability (needle passability) during administration, and also reduces irritation at the administration site when administered as an intramuscular or subcutaneous injection. The microspheres of the present disclosure can be administered to patients, for example, as an aqueous suspension injection containing microspheres containing Compound (I), a vehicle therefor, and water for injection. Alternatively, the microspheres of the present disclosure can be administered to patients as an oily suspension injection containing, for example, microspheres containing Compound (I), a vehicle therefor as needed, and an oil. A suitable oil is, for example, a triglyceride (particularly a medium-chain fatty acid triglyceride). The content of the microspheres in the suspension injection of the present disclosure is not particularly limited as long as the microspheres are dispersed in the injection, but is typically about 5 to 50% by weight, preferably about 10 to 40% by weight, and more preferably about 10 to 30% by weight. Examples of vehicles used in the present disclosure include the suspending agents, isotonicity agents, buffers, pH adjusters, etc., described above.
[0117] As used herein, the term "therapeutically effective amount" refers to an amount effective to provide a therapeutic benefit, such as alleviation of symptoms, when administered to a human or non-human. The specific dose of a substance administered to provide a therapeutic benefit will, of course, be determined by specific circumstances, such as the specific substance administered, the route of administration, the condition being treated, and the individual being treated. For example, a pharmaceutical formulation may contain 1 to 70% by weight of compound (I) or a salt thereof, calculated as compound (I).
[0118] For example, a daily dosage that can provide satisfactory results for subcutaneous or intramuscular administration may be on the order of about 0.001 to 1.5 mg / kg. The recommended daily dosage for subcutaneous or intramuscular administration is in the range of about 0.1 mg to 500 mg, more preferably 0.1 to 100 mg, and may be administered preferably once or in 2 to 4 divided doses per day. Thus, a unit dosage form for subcutaneous or intramuscular administration may contain, for example, about 0.1 mg to 500 mg of Compound (I) or a salt thereof, in terms of Compound (I), together with a pharmaceutically acceptable diluent or carrier. The upper or lower limit of this range (0.1 mg to 500 mg) may be, for example, 0.2, 0.5, 1, 2, 3, 5, 10, 20, 50, 100, 200, 300, or 400 mg. For example, the range is preferably 0.2 to 100 mg or 0.5 to 50 mg, and more preferably 0.5 to 10 mg.
[0119] As used herein, the term "pharmaceutically acceptable" refers to a compound, a composition containing the compound, or an administration form thereof that does not cause excessive toxicity, irritation, allergic response, etc., and has a reasonable benefit / risk ratio appropriate for application to humans or animals.
[0120] Although not particularly limited, a pharmaceutical preparation containing Compound (I) or a salt thereof is preferably, for example, an injection. Examples of the injection include an injection for intramuscular administration and an injection for subcutaneous administration, and an injection for subcutaneous administration is particularly preferred.
[0121] It should be noted that in this specification, the term "comprising" includes "consisting essentially of" and "consisting of." Furthermore, the present disclosure encompasses any and all combinations of the constituent elements described in this specification.
[0122] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to identify the subject matter encompassed by the present disclosure, i.e., the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described herein.
[0123] Hereinafter, the embodiments of the present disclosure will be described more specifically with reference to examples, but the embodiments of the present disclosure are not limited to the following examples.
[0124] The following abbreviations may be used in this specification: REX: Reference Example Number EX: Example Number STR: Structural Formula Data: Physical Property Data (NMR1: Dimethylsulfoxide-d 6 During 1 δ (ppm) in H-NMR; NMR2: CDCl 3 During 1 δ (ppm) in H-NMR; NMR3: CD 3 During OD 1 δ (ppm) in H-NMR; NMR4: CD 3 During CO2D 1 δ (ppm) in H-NMR, or MS: mass spectrum). Furthermore, the following abbreviations may be used for compound names and reagent names.
[0125]
[0126] In the following examples, "room temperature" generally refers to about 10°C to about 35°C. Ratios shown for mixed solvents are by volume unless otherwise specified. % refers to % by weight unless otherwise specified.
[0127] 1 H-NMR (proton nuclear magnetic resonance spectrum) was measured using a Fourier transform NMR (either Bruker AVANCE III 400 (400 MHz), Bruker AVANCE NEO 400 (400 MHz), or Bruker AVANCE III HD (500 MHz)).
[0128] Example 1 (EX1) To a mixture of 7-(4-(benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1H-quinolin-2-one (3.0 g), MeCN (30 mL), and DCM (90 mL), NaI (2.074 g), KCO (1.913 g), and di-tert-butyl(chloromethyl)phosphate (3.58 g) were added and stirred at room temperature. After 3 days, di-tert-butyl(chloromethyl)phosphate (1.790 g) and NaI (1.037 g) were added and stirred. After an additional 4 days, water was added to the reaction mixture and stirred. The organic layer was extracted and concentrated under reduced pressure. This was dissolved in DCM (90 mL), and then TFA (5.33 mL) was added and stirred at room temperature for 3 hours. To the reaction mixture was added 1N aqueous NaOH (138 mL) and stirred for 20 minutes. The aqueous layer was separated from the reaction mixture and washed with DCM and EtO. To the aqueous layer was added AcOH (3.96 mL) and stirred at room temperature for 1 hour. The precipitated solid was collected by filtration to give the crude product. The crude product was purified by reverse-phase silica gel column chromatography (0.1% AcOH MeCN / 0.1% AcOH HO) and concentrated under reduced pressure to give (4-(benzo[b]thiophen-4-yl)-1-((4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.71 g). NMR1; 1.77-1.89 (2H, m), 1.89-2.01 (2H, m), 3.37-3.86 (11H, m), 4.10 (2H, t, J = 6.3 Hz), 5.11 (2H, d, J = 9.0 Hz), 6.29 (1H, d, J = 9.4 Hz), 6.80 (1H, dd, J = 2.4 Hz). 8.7Hz), 6.95-7.05(2H, m), 7.31(1H, dd, J=7.9, 7.9Hz), 7.51(1H, d, J=5.5Hz), 7.54(1H, d, J=8.7Hz), 7.71(1H, d, J=8.1Hz), 7.76(1H, d, J=5.5Hz), 7.79(1H, d, J=9.5Hz), 11.93(1H, br).
[0129] Example 2 (EX2) Under a nitrogen atmosphere, a mixture of (4-(benzo[b]thiophen-4-yl)-1-(4-(((2-(tert-butoxy)quinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl tert-butyl phosphate (15.7 g), AcOH (42.3 mL), and TFA (14.1 mL) was stirred at 40°C for 1.5 hours. The reaction mixture was cooled to below 10°C, and a solution of AcONa (19.6 g) in water (170 mL) / MeCN (70.7 mL) was added, followed by washing with water (30 mL). The mixture was stirred at room temperature for 1 hour, and then water (71 mL) was added, followed by stirring at 0°C for 1 hour. The precipitated crystals were separated by solid-liquid separation, washed with water (71 mL), MeCN / water (1:4, 71 mL), and then cooled to 40°C. After drying under air for 12 hours, (4-(benzo[b]thiophen-4-yl)-1-((4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (13.81 g) was obtained. NMR1; 1.75-1.90 (2H, m), 1.90-2.00 (2H, m), 3.40-3.85 (11H, m), 4.09 (2H, t, J = 6.4 Hz), 5.11 (2H, d, J = 9.2 Hz), 6.29 (1H, d, J = 9.6 Hz), 6.80 (1H, dd, J = 2.4 Hz, 8.8 Hz), 6.95-7.05 (2H, m), 7.31(1H, dd, J=7.9Hz, 7.9Hz), 7.51(1H, d, J=5.6Hz), 7.54(1H, d, J=8.8Hz), 7.71(1H, d, J=8.0Hz), 7.76(1H, d, J=5.6Hz), 7.79(1H, d, J=9.6Hz), 11.93(1H, br).
[0130] Example 3 (EX3) Di-tert-butyl (chloromethyl) phosphate (1.82 g) was dissolved in MeCN / DCM (1 / 1) (60 mL), and 7-((4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-(tert-butoxy)quinoline (2.2 g) was added. The mixture was purged with nitrogen, shielded from light with aluminum foil, and stirred overnight at 40°C. The reaction mixture was concentrated under reduced pressure to remove most of the DCM, and then extracted with AcOEt / MeOH (9 / 1) and 10% aqueous NaSO. The organic layer was separated and concentrated under reduced pressure. AcOH (30 mL) was added to the residue, and the mixture was stirred at 40°C for 2 hours. The reaction mixture was concentrated under reduced pressure, and toluene was added, followed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH). 4-(benzo[b]thiophen-4-yl)-1-(((diethoxyphosphoryl)oxy)methyl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium iodide (3.1 g) was obtained. Acetone (120 mL) and NaI (2.55 g) were added to this, and the mixture was stirred at 60°C overnight. The mixture was returned to room temperature, the liquid was removed, and water (50 mL) and AcOH (2.5 mL) were added to the residue under ice-cooling. Water (80 mL) was added, and the mixture was stirred at room temperature for 8 hours. The precipitate was collected by filtration and washed with water. After drying under reduced pressure, it was purified by silica gel column chromatography (DCM / MeOH). After crystallization with MeCN / water, it was collected by filtration and washed with water. The obtained solid was dried under reduced pressure. (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl ethyl phosphate (1.1 g) was obtained.NMR1; 1.13(3H, t, J=7.1Hz), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 3.38-3.49(4H, m), 3.53-3.66(4H, m), 3.70-3.82(4H, m), 4.10(2H, t, J=6.1Hz), 5.09(2H, d, J=9.1Hz), 6.30(1H, d, J=9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.7Hz), 6.89(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, t, J=7.8Hz), 7.51(1H, d, J=5.5Hz), 7.56(1H, d, J=8.7Hz), 7.71(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.80(1H, d, J=9.1Hz), 11.69(1H, s).。
[0131] Example 4 (EX4) MeCN (44 mL) and water (44 mL) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-(tert-butoxy)quinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl tert-butyl phosphate (11.1 g), and the mixture was stirred at 45°C, followed by the addition of water (22 mL). After confirming the disappearance of the starting materials, NaHCO3 (1.1 g) was added, and the mixture was concentrated under reduced pressure and extracted with 10% MeOH / DCM (100 mL). The obtained organic layer was concentrated, and the crude product was purified by silica gel column chromatography (DCM / MeOH) to obtain (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl tert-butyl phosphate (8.7 g). NMR3; 1.47(9H, s), 1.95-2.04(2H, m), 2.05-2.15(2H, m), 3.40-3.60(4H, m), 3.65-3.70(2H, m), 3.70-3.80(2H, m), 3.85-3.95(2H, m), 4.20(2H, t, J=6.0Hz), 5.16(2H, d, J=8.0Hz), 6.44(1H, d, J= 9.6Hz), 6.88-6.92(2H, m), 7.03(1H, dd, J=0.4, 7.6Hz), 7.29(1H, t, J=8.0Hz), 7.49(1H, dd, J=0.8, 5.6Hz), 7.55-7.58(2H, m), 7.64(1H, d, J=8.0Hz), 7.87(1H, d, J=7.6Hz).
[0132] Example 5 (EX5) Isopropyl alcohol (10 mL), water (2 mL), and WSC.HCl (317 mg) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (300 mg) at room temperature, followed by stirring at 70°C for 10 hours. The reaction solution was concentrated, water was added, and the mixture was extracted with DCM / MeOH (9 / 1). The organic layer was concentrated, and the residue was purified by silica gel column chromatography (DCM / MeOH). (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl isopropyl phosphate (44 mg) was obtained. NMR1; 1.14(6H, d, J=6.2Hz), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 3.41-3.49(4H, m), 3.53-3.66(4H, m), 3.66-3.82(2H, m), 4.10(2H, t, J=6.1Hz), 4.25-4.34 (1H, m), 5.08(2H, d, J=7.2Hz), 6.30(1H, dd, J=2.0Hz, 9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.7Hz), 6.90(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, t, J= 7.8Hz), 7.51(1H, d, J=5.5Hz), 7.56(1H, d, J=8.7Hz), 7.71(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.80(1H, d, J=9.1Hz), 11.69(1H, s).
[0133] Example 6 (EX6) 1,3-propanediol (10 mL), water (2 mL), and WSC.HCl (212 mg) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (300 mg) at room temperature, followed by stirring at 40°C. After 30 minutes, the temperature was raised to 50°C, and after another 30 minutes, the temperature was raised to 60°C. After another 2 hours, the temperature was returned to room temperature, and azeotropic distillation was performed with AcOEt. The residue was purified by silica gel column chromatography (DCM / MeOH). The mixture was dispersed and washed with AcOEt, and insoluble matter was collected by filtration. Drying under reduced pressure gave (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (3-hydroxypropyl) phosphate (200 mg). NMR1; 1.57-1.68(2H, m), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 3.40-3.52(6H, m), 3.53-3.66(4H, m), 3.70-3.82(4H, m), 4.10(2H, t, J=6.1Hz), 4.70(1H, t, J=5.6Hz), 5.10(2H, d, J=9.0Hz), 6.30(1H, d, J=9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.7Hz), 6.89(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, t, J=7.8Hz), 7.51(1H, d, J=5.5Hz), 7.56(1H, d, J=8.7Hz), 7.71(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.81(1H, d, J=9.4Hz), 11.67(1H, s).
[0134] Example 7 (EX7) Diethylene glycol monomethyl ether (10.00 mL), water (2 mL), and WSC.HCl (353 mg) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (500 mg) at room temperature, followed by stirring at 40° C. After 3 hours, additional WSC.HCl (176 mg) was added. The mixture was stirred at 40° C. for 3 hours. Water was added to the reaction solution, followed by extraction with DCM / MeOH (9 / 1). The organic layer was concentrated, and the residue was purified by silica gel column chromatography (DCM / MeOH) to obtain (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl(2-(2-methoxyethoxy)ethyl)phosphate (188 mg). NMR1; 1.78-1.89(2H, m), 1.89-2.01(2H, m), 3.21(3H, s), 3.40-3.48(6H, m), 3.42-3.49(4H, m), 3.53-3.68(4H, m), 3.70-3.85(4H, m), 4.10(2H, t, J=5.2Hz), 5.09(2H, d, J=9.0Hz), 6.30(1H, d, J=9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.7Hz), 6.89(1H, d, J=2.3Hz), 7.01(1H, d, J=7.3Hz), 7.32(1H, t, J=7.8Hz), 7.51(1H, d, J=5.5Hz), 7.56(1H, d, J=8.7Hz), 7.71(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.80(1H, d, J=9.1Hz), 11.67(1H, s).
[0135] Example 8 (EX8) Acetone / water (9 / 1) (10 mL), ethyl glycolate (3 mL), and WSC.HCl (529 mg) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (500 mg) at room temperature, followed by stirring at 40° C. for 5 hours and then at room temperature overnight. DCM / MeOH (9 / 1) and water were added to the reaction solution, and the precipitate was collected by filtration. The organic layer of the filtrate was concentrated, combined with the precipitate, and purified by silica gel column chromatography (DCM / MeOH) to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-ethoxy-2-oxoethyl) phosphate (16 mg). NMR1; 1.18(3H, t, J=7.1Hz), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 3.42-3.49(4H, m), 3.51-3.68(4H, m), 3.70-3.82(2H, m), 4.10(2H, J=9.6Hz), 4.06-4.15 (2H, m), 4.35 (2H, d, J=9.6Hz), 5.12(2H, d, J=8.8Hz), 6.30(1H, dd, J=1.8Hz, 9.4Hz), 6.83(1H, dd, J=2.4Hz, 8.7Hz), 6.87(1H, d, J=2.3Hz), 7.01(1H, d, J=7.5Hz), 7.33(1H, t, J=7.8Hz), 7.52(1H, d, J=5.5Hz), 7.57(1H, d, J=9.0Hz), 7.72(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.81(1H, d, J=9.1Hz), 11.65(1H, s).
[0136] Example 9 (EX9) (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.0 g) was suspended in a mixture of ethylene glycol (10 mL) and water (1 mL), and WSC·HCl (1.06 g) was added, followed by stirring at 45° C. for 5 hours. Acetone and AcOEt were added to the reaction mixture, and the mixture was concentrated under reduced pressure three times to remove water azeotropically. The concentrated solution was directly purified by medium-pressure liquid chromatography (DCM / MeOH). Water and a mixed solvent of DCM-MeOH = 4:1 were added to the obtained product, and the mixture was stirred and extracted. The organic layer was concentrated under reduced pressure, and acetone was added to the obtained oil, followed by stirring overnight at room temperature. The precipitated solid was collected by filtration and air-dried to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-hydroxyethyl) phosphate (71 mg). NMR1; 1.78-1.88 (2H, m), 1.90-1.99 (2H, m), 3.42-3.48 (2H, m), 3.49-3.55 (2H, m), 3.56-3.68 (4H, m), 3.72-3.80 (4H, m), 4.10 (2H, t, J = 6.0Hz), 5.11 (2H, d, J = 9.5Hz), 6.30 (1H, dd, J = 9.5Hz, 1.8Hz), 6.83 (1H, dd, J = 8.6Hz, 2.4Hz), 6.88 (1H, d, J = 2.4Hz), 7.00 (1H, d, J = 7.4Hz), 7.32 (1H, t, J = 7.9Hz), 7.51 (1H, d, J = 5.5Hz), 7.56 (1H, d, J = 8.7Hz), 7.71 (1H, d, J = 8.1Hz), 7.77 (1H, d, J = 5.5Hz), 7.80 (1H, d, J = 9.4Hz), 11.7 (1H, s).
[0137] Example 10 (EX10) (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.0 g) was suspended in a mixture of 1,4-butanediol (20 mL) and water (4 mL), and WSC.HCl (1.06 g) was added and stirred at 60°C for 5 hours. Acetone and AcOEt were added to the reaction mixture, which was then concentrated under reduced pressure three times to azeotropically remove water. The concentrated solution was directly purified twice by medium-pressure liquid chromatography (first run: silica gel, second run: amino silica gel, eluent: DCM / MeOH). The resulting amorphous solid was suspended in water (5 mL), and acetone was added to dissolve it. After standing overnight at room temperature, the precipitated crystals were collected by filtration and dried overnight at 25°C under a blower to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (4-hydroxybutyl) phosphate (438 mg). NMR1; 1.39-1.49 (2H, m), 1.50-1.58 (2H, m), 1.78-1.88 (2H, m), 1.89-1.99 (2H, m), 3.37-3.42 (2H, m), 3.42-3.48 (2H, m), 3.53-3.67 (4H, m), 3.68-3.80 (4H, m), 4.10 (2H, t, J = 6.1Hz), 4.43 (1H, t, J = 5.2Hz), 5.09 (2H, d, J = 9.1Hz), 6.30 (1H, d, J = 9.4Hz), 6.82 (1H, dd, J = 8.6Hz, 2.4Hz), 6.89 (1H, d, J = 2.4Hz), 7.01 (1H, d, J = 7.6Hz), 7.32 (1H, t, J = 7.9Hz), 7.51 (1H, d, J = 5.6Hz), 7.56 (1H, d, J = 8.7Hz), 7.71 (1H, d, J = 8.0Hz), 7.76 (1H, d, J = 5.5Hz), 7.80 (1H, d, J = 9.5Hz), 11.7 (1H, s).
[0138] Example 11 (EX11) (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.0 g) and 1,8-octanediol (3 g) were suspended in a mixed solvent of acetone (8 mL) and water (2 mL), and WSC·HCl (0.71 g) was added and stirred at 50°C for 3 hours. Acetone and AcOEt were added to the reaction solution, and the mixture was concentrated under reduced pressure three times to azeotropically remove water. The concentrated solution was directly purified twice by medium-pressure liquid chromatography (first run: silica gel, second run: amino silica gel, eluent: DCM / MeOH). The resulting amorphous solid was suspended in water (5 mL) and dissolved by adding acetone. After standing overnight at room temperature, the precipitated crystals were collected by filtration and dried overnight at 25°C under a blower to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (8-hydroxyoctyl) phosphate (176 mg).NMR1; 1.18-1.29 (8H, m),1.33-1.42 (2H, m), 1.45-1.52 (2H, m), 1.78-1.87 (2H, m), 1.88-1.98 (2H, m), 3.42-3.50 (4H, m), 3.53-3.80 (8H, m), 4.10 (2H, t, J = 6.1Hz), 4.34 (1H, t, J = 5.2Hz), 5.00 (2H, d, J = 9.0Hz), 6.30 (1H, dd, J = 9.4Hz, 1.4Hz), 6.81 (1H, dd, J = 8.6Hz, 2.4Hz), 6.89 (1H, d, J = 2.4Hz), 7.01 (1H, d, J = 7.4Hz), 7.32 (1H, t, J = 7.8Hz), 7.51 (1H, dd, J = 5.6Hz, 0.4Hz), 7.56 (1H, d, J = 8.7Hz), 7.71 (1H, d, J = 8.1Hz), 7.76 (1H, d, J = 5.5Hz), 7.80 (1H, d, J = 9.5Hz), 11.7 (1H, s).。
[0139] Example 12 (EX12) (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.0 g) was suspended in a mixture of 2-methoxyethanol (20 mL) and water (2 mL), and WSC.HCl (1.06 g) was added and stirred at 60°C for 3 hours. Acetone and AcOEt were added to the reaction mixture, and the mixture was concentrated under reduced pressure three times to azeotropically remove water. The concentrated solution was directly purified twice by medium-pressure liquid chromatography (first run: silica gel, second run: amino silica gel, eluent: DCM / MeOH). The resulting amorphous solid was suspended in water (5 mL), and acetone was added to dissolve it. After standing overnight at room temperature, the precipitated crystals were collected by filtration and dried overnight at 25°C under a blower to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-methoxyethyl) phosphate (320 mg). NMR1; 1.79-1.88 (2H, m), 1.89-1.98 (2H, m), 3.24 (3H, s), 3.40-3.48 (4H, m), 3.55-3.67 (4H, m), 4.10 (2H, t, J = 6.1Hz), 5.09 (2H, d, J = 9.0Hz), 6.30 (1H, d, J = 9.5Hz), 6.82 (1H, dd, J = 8.7Hz, 2.4Hz), 6.89 (1H, d, J = 2.4Hz), 7.01 (1H, d, J = 7.4Hz), 7.32 (1H, t, J = 7.8Hz), 7.51 (1H, d, J = 5.5Hz), 7.56 (1H, d, J = 8.7Hz), 7.71 (1H, d, J = 8.0Hz), 7.77 (1H, d, J = 5.5Hz), 7.80 (1H, d, J = 9.5Hz), 11.7 (1H, s).
[0140] Example 13 (EX13) (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (1.0 g) was suspended in a mixed solution of ethylene glycol monoisopropyl ether (20 mL) and water (2 mL), and WSC.HCl (0.71 g) was added and stirred at 50°C for 7 hours. Acetone and AcOEt were added to the reaction solution, and the mixture was concentrated under reduced pressure three times to azeotropically remove water. The concentrated solution was directly purified twice by medium-pressure liquid chromatography (first run: silica gel, second run: amino silica gel, eluent: DCM / MeOH). The resulting amorphous solid was suspended in water (5 mL) and dissolved by adding acetone (15 mL). After standing at room temperature for 5 days, the precipitated crystals were collected by filtration and dried overnight at 25°C with a blower to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-isopropoxyethyl) phosphate (290 mg). NMR1; 1.06 (6H, d, J = 6.1Hz), 1.78-1.88 (2H, m), 1.89-2.00 (2H, m), 3.42-3.48 (4H, m), 3.49-3.68 (4H, m), 3.72-3.81 (4H, m), 4.10 (2H, t, J = 6.0Hz), 5.10 (2H, d, J = 9.1Hz), 6.30 (1H, dd, J = 9.4Hz, 1.4Hz), 6.82 (1H, dd, J = 8.6Hz, 2.4Hz), 6.89 (1H, d, J = 2.4Hz), 7.01 (1H, d, J = 7.4Hz), 7.32 (1H, t, J = 7.9Hz), 7.51 (1H, d, J = 5.5Hz), 7.56 (1H, d, J = 8.7Hz), 7.71 (1H, d, J = 8.0Hz), 7.77 (1H, d, J = 5.5Hz), 7.80 (1H, d, J = 9.5Hz), 11.7 (1H, s).
[0141] Example 14 (EX14) To a solution of (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-bromoethyl)phosphate (300 mg) in THF (12 mL) was added morpholine (1.2 mL) at room temperature, followed by stirring at 40°C for 5 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (DCM / MeOH). The mixture was dissolved in MeCN / HO (1 / 1), and then MeCN was added. The precipitate was collected by filtration and washed with MeCN. The extract was dried at room temperature to obtain (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (2-morpholinoethyl) phosphate (164 mg). NMR1; 1.78-1.89(2H, m), 1.89-2.01(2H, m), 2.34-2.41(4H, m), 2.46 (2H, t, J=6.1Hz), 3.42-3.49(4H, m), 3.50-3.68(8H, m), 3.71-3.85(4H, m), 4.10(2H, t, J=6.1Hz), 5.10(2H, d, J=9.1Hz), 6.30(1H, d, J=9.4Hz), 6.82(1H, dd, J=2.4, 8.7Hz), 6.89(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, t, J=7.8Hz), 7.51(1H, d, J=5.5Hz), 7.56(1H, d, J=8.7Hz), 7.71(1H, d, J=8.0Hz), 7.77(1H, d, J=5.6Hz), 7.80(1H, d, J=9.1Hz), 11.68(1H, s).
[0142] Example 15 (EX15) Pyridine (4 mL) and acetic anhydride (2 mL) were added to (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl (3-hydroxypropyl) phosphate (200 mg) at room temperature, followed by stirring overnight. The reaction solution was concentrated and azeotroped with toluene. The residue was purified by silica gel column chromatography (DCM / MeOH). EtOH / HO (1 / 1) was added, and the mixture was dispersed and washed at 40°C, and insoluble matter was collected by filtration. The residue was washed with water and dried at room temperature to obtain 3-acetoxypropyl ((4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl) phosphate (126 mg). NMR3; 1.92-2.05(7H, m), 2.04-2.16(2H, m), 3.45-3.56(4H, m), 3.64-3.73 (2H, m), 3.74-3.83(2H, m), 3.86-3.93(2H, m), 4.01(2H, q, J=6.2Hz), 4.15-4.25(4H, m), 4.52-4.65(4H, m), 5.20(2H, d, J=8.1Hz), 6.44(1H, d, J=9.4Hz), 6.89(1H, d, J=2.4Hz), 6.92(1H, dd, J=2.4, 8.7Hz), 7.05(1H, d, J=7.7Hz), 7.30(1H, t, J=7.9Hz), 7.49(1H, dd, J=0.8, 5.6Hz), 7.57(1H, d, J=5.2Hz), 7.59(1H, d, J=2.0Hz), 7.65(1H, d, J=8.1Hz), 7.88(1H, d, J=9.4Hz).
[0143] Example 16 (EX16) To a stirred mixture of (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (632 mg), acetone (6 mL), water (2 mL), and DIPEA (0.524 mL) was added chloromethyl hexanoate (494 mg) and the mixture was stirred under reflux. After 8 hours, the mixture was cooled to room temperature, and then acetone (2 mL) was added and the mixture was stirred. The precipitated solid was collected by filtration. The mixture was washed with acetone / water (3:1) and then acetone to obtain a crude product. The product was purified by silica gel column chromatography (DCM / MeOH). Acetone (3 mL) and water (1 mL) were added, and the precipitated solid was collected by filtration. The extract was washed with acetone and dried to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl((hexanoyloxy)methyl) phosphate (269 mg). NMR1; 0.79(3H, t, J=6.9Hz), 1.12-1.27(4H, m), 1.42-1.53(2H, m), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 2.30(2H, t, J=7.5Hz), 3.40-3.52(4H, m), 3.52-3.70(4H, m), 3.70-3.82(2H, m), 4.09(2H, t, J=6.0Hz), 5.09(2H, d, J=8.9Hz), 5.42(2H, d, J=12.7Hz), 6.30(1H, dd, J=1.9Hz, 9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.6Hz), 6.86(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, dd, J=7.9Hz, 7.9Hz), 7.52(1H, dd, J=0.6Hz, 5.5Hz), 7.56(1H, d, J=8.6Hz), 7.72(1H, d, J=8.1Hz), 7.77(1H, d, J=5.5Hz), 7.81(1H, d, J=9.4Hz), 11.64(1H, s).
[0144] Example 17 (EX17) To a stirred mixture of (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (630 mg), acetone (6 mL), water (3 mL), and DIPEA (0.522 mL) was added chloromethyl decanoate (220 mg) and the mixture was stirred under reflux. After 1 hour, additional chloromethyl decanoate (220 mg) was added. After another hour, additional chloromethyl decanoate (220 mg) was added. After stirring for another 2 hours, additional acetone (3 mL) was added. After another 3 hours, additional DIPEA (0.348 mL) and chloromethyl decanoate (220 mg) were added. After 1 hour, additional chloromethyl decanoate (220 mg) was added. After an additional 1.5 hours, heating was discontinued, the mixture was returned to room temperature, and stirred overnight. After stirring under reflux for 2 hours, the mixture was returned to room temperature and stirred for an additional hour. Acetone (3 mL) was added, and the precipitated solid was collected by filtration. The mixture was washed with acetone / water (3:1) and then with acetone to obtain a crude product. Acetone (5 mL) and water (1 mL) were added, and the mixture was stirred under reflux for 30 minutes. After cooling to room temperature, the precipitated solid was collected by filtration, washed with acetone / water (3:1) and then with acetone, and dried to obtain (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl((decanoyloxy)methyl)phosphate (370 mg).NMR1; 0.82(3H, t, J=6.9Hz), 1.11-1.26(12H, m), 1.41-1.51(2H, m), 1.78-1.89(2H, m), 1.89-2.01(2H, m), 2.30(2H, t, J=7.5Hz), 3.42-3.50(4H, m), 3.53-3.69(4H, m), 3.71-3.82(2H, m), 4.09(2H, t, J=6.0Hz), 5.09(2H, d, J=8.9Hz), 5.42(2H, d, J=12.8Hz), 6.30(1H, dd, J=1.8Hz, 9.5Hz), 6.82(1H, dd, J=2.4Hz, 8.6Hz), 6.85(1H, d, J=2.3Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, dd, J=7.9Hz, 7.9Hz), 7.52(1H, dd, J=0.42Hz, 5.5Hz), 7.56(1H, d, J=8.6Hz), 7.71(1H, d, J=8.1Hz), 7.77(1H, d, J=5.5Hz), 7.80(1H, d, J=9.5Hz), 11.63(1H, s).。
[0145] Example 18 (EX18) To a stirred mixture of (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (632 mg), acetone (6 mL), water (2 mL), and DIPEA (0.524 mL) was added chloromethyl cyclohexanecarboxylate (530 mg) and the mixture was stirred under reflux. After 8 hours, the mixture was cooled to room temperature, and then acetone (2 mL) was added and the mixture was stirred. The precipitated solid was collected by filtration and washed with acetone / water (3:1) and then acetone to obtain a crude product. The product was purified by silica gel column chromatography (DCM / MeOH). Acetone (3 mL) and water (1 mL) were added, and the precipitated solid was collected by filtration. The residue was washed with acetone and dried to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl(((cyclohexanecarbonyl)oxy)methyl) phosphate (392 mg).NMR1; 1.05-1.39(5H, m), 1.46-1.55(1H, m), 1.56-1.66(2H, m), 1.75-1.89(4H, m), 1.89-2.00(2H, m), 2.23-2.34(1H, m), 3.40-3.50(4H, m), 3.52-3.70(4H, m), 3.70-3.82(2H, m), 4.09(2H, t, J=6.0Hz), 5.10(2H, d, J=9.1Hz), 5.42(2H, d, J=12.5Hz), 6.30(1H, dd, J=1.8Hz, 9.4Hz), 6.82(1H, dd, J=2.4Hz, 8.6Hz), 6.86(1H, d, J=2.4Hz), 7.01(1H, d, J=7.4Hz), 7.32(1H, dd, J=7.9Hz, 7.9Hz), 7.52(1H, dd, J=0.4Hz, 5.6Hz), 7.56(1H, d, J=8.7Hz), 7.72(1H, d, J=8.1Hz), 7.77(1H, d, J=5.5Hz), 7.81(1H, d, J=9.5Hz), 11.65(1H, s).。
[0146] Example 19 (EX19) To a stirred mixture of (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl hydrogen phosphate (632 mg), acetone (6 mL), water (2 mL), and DIPEA (0.524 mL) was added chloromethylcyclohexyl carbonate (578 mg) and the mixture was stirred under reflux. After 8 hours, the mixture was cooled to room temperature, and then acetone (2 mL) was added and the mixture was stirred. The precipitated solid was collected by filtration and washed with acetone / water (3:1) and then acetone to obtain a crude product. The product was purified by silica gel column chromatography (DCM / MeOH). Acetone (3 mL) and water (1 mL) were added, and the precipitated solid was collected by filtration. The extract was washed with acetone and dried to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl ((((cyclohexyloxy)carbonyl)oxy)methyl) phosphate (296 mg).NMR1; 1.04-1.17(1H, m), 1.18-1.37(4H, m), 1.37-1.47(1H, m), 1.52-1.63(2H, m), 1.75-1.89(4H, m), 1.89-2.00(2H, m), 3.42-3.50(4H, m), 3.53-3.70(4H, m), 3.70-3.81(2H, m), 4.09(2H, t, J=6.0Hz), 4.47-4.55(1H, m), 5.09(2H, d, J=8.5Hz), 5.43(2H, d, J=13.3Hz), 6.30(1H, dd, J=1.9Hz, 9.5Hz), 6.83(1H, dd, J=2.4Hz, 8.6Hz), 6.85(1H, d, J=2.3Hz), 7.00(1H, d, J=7.4Hz), 7.32(1H, dd, J=7.8Hz, 7.8Hz), 7.52(1H, dd, J=0.4Hz, 5.6Hz), 7.56(1H, d, J=8.6Hz), 7.72(1H, d, J=8.0Hz), 7.77(1H, d, J=5.5Hz), 7.81(1H, d, J=9.5Hz), 11.63(1H, s).。
[0147] Example 20 (EX20) To a solution of 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-(tert-butoxy)quinoline (500 mg) in MeCN / DCM (30 mL) (2 / 1), NaI (306 mg), KCO (282 mg), and dibutyl(chloromethyl)phosphate (528 mg) were added, the atmosphere was purged with nitrogen, and the mixture was shielded from light with aluminum foil and stirred overnight at 40°C. Dibutyl(chloromethyl)phosphate (132 mg) and NaI (77 mg) were added, and the mixture was stirred at 40°C for 8 hours. DCM and saturated aqueous NaHCO were added, and the mixture was extracted with DCM. The organic layer was concentrated, and to the residue were added MeCN (10 mL), water (5 mL), and AcOH (0.5 mL). The mixture was stirred at room temperature overnight. AcOEt / MeOH = 9 / 1 and water were added to the reaction system for extraction. The organic layer was concentrated, and the residue was purified by silica gel column chromatography (DCM / MeOH) to give 4-(benzo[b]thiophen-4-yl)-1-(((dibutoxyphosphoryl)oxy)methyl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium iodide (545 mg). NMR2; 0.92(6H, t, J=7.4Hz), 1.33-1.46(4H, m), 1.64-1.75(4H, m),1.94-2.04(2H, m) 2.13-2.25(2H m), 3.41-3.60(4H m), 3.85-4.18(8H, m), 4.20(4H, q, J=6.6Hz, 14.0Hz), 5.75(2H, d, J=8.7Hz), 6.42(1H, d, J=9.4Hz), 6.71(1H, dd, J=2.3Hz, 8.6Hz), 6.92(1H, d, J=7.4Hz), 7.12(1H, d, J=2.2Hz), 7.19(1H, t, J=7.9Hz), 7.30(1H, d, J=8.7Hz), 7.35-7.42(2H, m), 7.56(1H, s), 7.58(1H, d, J=2.2Hz), 11.04(1H, s).
[0148] Reference Example 1 (REX1) Under a nitrogen atmosphere, 7-(4-(benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1H-quinolin-2-one (15.0 g) and silver carbonate (20.0 g) were suspended in CPME (300 mL) in a 500 mL round-bottom flask, and 2-bromo-2-methylpropane (7.84 mL) was added. The mixture was stirred at 90°C for 9 hours in the dark. The insoluble matter was filtered through Celite and washed with AcOEt (150 mL). The solvent was evaporated under reduced pressure, and MeCN (180 mL) was added to the residue and stirred. The precipitated crystals were separated into solid and liquid, washed with MeCN (60 mL), and then dried under air at 40°C to obtain 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-(tert-butoxy)quinoline (16.0 g). NMR2; 1.69(9H, s), 1.75-1.83(2H, m), 1.89-1.96(2H, m), 2.55(2H, t, J=7.6Hz), 2.73(4H, m), 3.2(4H, m), 4.15(2H, t, J=6.4Hz), 6.64(1H, d, J=7.6Hz), 6.89(1H, d, J=7.6Hz), 6.99(1H, dd, J=8.8Hz, J=2.4Hz), 7.15(1H, d, J=2.4Hz), 7.27(1H, t, J=7.6Hz), 7.38-7.43(2H, m), 7.53-7.56(2H, m), 7.82(1H, d, J=8.4Hz).
[0149] Reference Example 2 (REX2) Under a nitrogen atmosphere, 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-(tert-butoxy)quinoline (16 g), NaI (9.8 g), and K2CO3 (9.0 g) were suspended in MeCN (240 mL) in a 1000 mL round-bottom flask, and di-tert-butyl(chloromethyl)phosphate (16.9 g) was added and stirred at 25-40°C for 2 days. Water (240 mL) was then added and the mixture was stirred at 45°C for 1 hour, after which most of the MeCN was distilled off under reduced pressure. The resulting crystals were cooled to 0°C, separated, washed with MeCN / water (1:4, 80 mL), and dried in vacuo at 40°C for 16 hours. The resulting crystals (19 g) were placed in a 1 L flask, and AcOEt (300 mL) and TEA (1 mL) were added and stirred for 30 min. After solid-liquid separation, the crystals were washed with AcOEt (150 mL) and dried in vacuo at 30 °C for 5 h to give (4-(benzo[b]thiophen-4-yl)-1-(4-((2-(tert-butoxy)quinolin-7-yl)oxy)butyl)piperazin-1-ium-1-yl)methyl tert-butyl phosphate (15.73 g). NMR3; 1.47(9H, s), 1.66(9H, s), 1.95-2.05(2H, m), 2.10-2.20(2H, m), 3.40-3.60(4H, m), 3.65-3.70(2H, m), 3.70-3.80(2H, m), 3.85-3.95(2H, m), 4.24(2H, t, J=5.6Hz), 5.15(2H, d, J=8.0Hz), 6.65(2H, d, J=8.8Hz), 7.00(1H, dd, J=8.8Hz, J=0.8Hz), 7.03(1H, dd, J=8.8Hz, J=2.4Hz), 7.18(1H, d, J=2.4Hz), 7.26(1H, t, J=8.0Hz), 7.49(1H, dd, J=5.6Hz, J=0.8Hz), 7.57-7.65(3H, m), 7.92(1H, d, J=8.8Hz).
[0150] Reference Example 3 (REX3) NaH (55% oil) (151 mg) was suspended in THF (10 mL), 7-(4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1H-quinolin-2-one (500 mg) was added, and chloromethyl hexanoate (570 mg) was added dropwise, followed by stirring at 50°C for 2 hours. After cooling to 0°C, the mixture was quenched with an aqueous ammonium chloride solution. Extraction with AcOEt was performed and the mixture was dried over NaSO. This was purified by medium-pressure silica gel column chromatography to give (7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl hexanoate (217 mg). NMR2; 0.85(3H, t, J=6.8Hz), 1.25-1.33(4H, m), 1.58-1.69 (2H, m), 1.70-1.85(2H, m), 1.85-1.95(m, 2H), 2.36(2H, t, J=7.5 Hz), 2.54(2H, t, J=7.4Hz), 2.67-2.78(4H, m), 3.15-3.25(4H, m), 4.08(2H, t, J=6.2Hz), 6.34(2H, brs), 6.52(1H, d, J=9.5Hz), 6.84(1H, dd, J=2.2Hz, 8.6Hz), 6.84-6.92(2H, m), 7.27(1H, dd, J=7.8Hz, 7.8Hz), 7.37-7.43(2H, m), 7.45(1H, d, J=8.6Hz), 7.55(1H, d, J=8.1Hz), 7.62(1H, d, J=9.5Hz).
[0151] Reference Example 4 (REX4) 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one (4.0 g) was dissolved in DCM (120 mL), and then a solution of iodomethyl piperidine-1-carboxylate (2.98 g) in DCM (10 mL) was added with stirring at room temperature, followed by stirring at room temperature for 2 hours. After standing overnight, the mixture was filtered, washed with DCM, and dried to obtain a crude product. This crude product was recrystallized from DCM / DMF (3 / 2) (140 mL). 4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)-1-(((piperidine-1-carbonyl)oxy)methyl)piperazin-1-ium iodide (4.06 g) was obtained. NMR1; 1.32-1.63(6H, m), 1.80-2.04(4H, m), 3.25-3.40(2H, m), 3.40-3.58(6H, m), 3.58-3.88(6H, m), 4.10(2H, t, J=5.6Hz), 5.55(2H, s), 6.32(1H, dd, J=1.4Hz, 9.5Hz), 6.74-6.95(2H, m), 7.04(1H, d, J=7.6Hz), 7.34(1H, dd, J=7.8Hz, 7.8Hz), 7.54(1H, d, J=5.5Hz), 7.59(1H, d, J=9.4Hz), 7.73(1H, d, J=8.1Hz), 7.79(1H, d, J=5.5Hz), 7.82(1H, d, J=9.5Hz), 11.64(1H, s).
[0152] Reference Example 5 (REX5) In the same manner as in Reference Example 4, 4-(benzo[b]thiophen-4-yl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)-1-((propionyloxy)methyl)piperazin-1-ium iodide was obtained. NMR1; 1.07(3H, t, J=7.4Hz), 1.71-2.00(4H, m), 2.56(2H, q, J=7.4Hz), 3.47-3.52(4H, m), 3.63-3.71(2H, m), 3.71-3.86(4H, m), 4.10(2H, t, J=5.6Hz), 5.55(2H, s), 6.32(1H, dd, J=1.5Hz, 9.4Hz), 6.77-6.87(2H, m), 7.03(1H, d, J=7.6Hz), 7.34(1H, dd, J=7.9Hz, 7.9Hz), 7.53(1H, d, J=5.6Hz), 7.59(1H, d, =8.5Hz), 7.73(1H, d, J=8.0Hz), 7.78(1H, d, J=5.5Hz), 7.82(1H, d, J=9.5Hz), 11.65(1H, s).
[0153] Reference Example 6 (REX6) In the same manner as in Reference Example 4, 4-(benzo[b]thiophen-4-yl)-1-((hexanoyloxy)methyl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium iodide was obtained. NMR1; 0.83(3H, t, J=6.9Hz), 1.13-1.31(4H, m), 1.46-1.58(2H, m), 1.80-2.02(4H, m), 2.44-2.55(2H, m), 3.48-3.54(4H, m), 3.64-3.88(6H, m), 4.10(2H, t, J=5.5Hz), 5.57(2H, s), 6.29-6.37(1H, m), 6.80-6.88(2H, m), 7.05(1H, d, J= 7.5Hz), 7.35(1H, dd, J=7.9Hz, 7.9Hz), 7.54(1H, d, J=5.5Hz), 7.60(1H, d, =9.4Hz), 7.74(1H, d, J=8.1Hz), 7.79(1H, d, J=5.5Hz), 7.84(1H, d, J=9.5Hz), 11.65(1H, s).
[0154] Reference Example 7 (REX7) In the same manner as in Reference Example 4, 4-(benzo[b]thiophen-4-yl)-1-((((hexyloxy)carbonyl)oxy)methyl)-1-(4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butyl)piperazin-1-ium iodide was obtained. NMR1; 0.85(3H, t, J=6.9Hz), 1.17-1.37(6H, m), 1.50-1.67(2H, m), 1.77-2.03(4H, m), 3.40-3.56(4H, m), 3.63-3.90(6H, m), 4.09(2H, t, J=5.7Hz), 4.18(2H, t, J=6.7Hz), 5.61(2H, s), 6.31(1H, dd, J=1.8Hz, 9.5Hz), 6.76-6.85(2H, m), 7.03(1H, d, J=7.4Hz), 7.34(1H, dd, J=7.9Hz, 7.9Hz), 7.54(1H, dd, J=0.4Hz, 5.5Hz), 7.58(1H, d, J=8.8Hz), 7.73(1H, d, J=8.1Hz), 7.79(1H, d, J=5.5Hz), 7.82(1H, d, J=9.5Hz), 11.63(1H, s).
[0155] The structural formulae of the Reference Example compounds (Reference Examples 1 to 7) and Example compounds (Examples 1 to 20) obtained by methods similar to those described above are shown in the following table.
[0156]
[0157] In addition, compounds according to Examples other than those described above were also synthesized and investigated. The numbering, structural formula, production method, and NMR analysis data for these compounds are listed below in a table. For convenience, each Example is numbered as "EX N" (where N is an integer from 1 to 161). "EX N" may also be written as "Example N," etc. The numbering, structural formula, production method, and NMR analysis data for the compounds used in the synthesis of each Example are listed below in a table as Reference Examples 8 to 67. For convenience, each Reference Example is numbered as "REX M" (where M is an integer from 8 to 67). "REX M" may also be written as "Reference Example M," etc.
[0158] The obtained compounds were used in the following test examples. The compounds of Reference Examples 3 and 4 are the compounds described in Examples 58 and 706 of Patent Document 2 (WO 2013 / 035892), respectively.
[0159] Cytotoxicity test using HL-60 cells (1) Cell culture HL-60 cell line (human acute promyelocytic leukemia) was maintained and cultured in RPMI1640 containing 20% fetal bovine serum (FBS) at 37°C in the presence of 95% air / 5% CO2. Prior to evaluation, the cells were pre-cultured in the presence of 10 nM phorbol 12-myristate 13-acetate (PMA) for approximately 72 hours to induce differentiation into macrophage-like cells.
[0160] (2) Treatment with evaluation compound The evaluation compound was dissolved in DMSO to prepare a 30 mmol / L solution (or suspension). Each DMSO solution was diluted 100-fold with RPMI1640 containing 2% FBS (final compound concentration: 300 μmol / L) to prepare a treatment solution. The culture supernatant of differentiated HL-60 cells was removed, and each treatment solution was added. After approximately 24 hours of culture, cytotoxicity was evaluated. The compound of Reference Example 3, which showed irritation when administered subcutaneously to dogs, was used as a positive control compound, and risperidone, which is commercially available as a subcutaneous injection formulation, was used as a negative control compound.
[0161] (3) Cytotoxicity Evaluation Using a commercially available kit (Cytotoxicity LDH Assay Kit-WST, Dojindo) and a plate reader (TECAN infinite M1000), lactate dehydrogenase (LDH) activity in the treatment solution was measured after approximately 24 hours of exposure to cells. Using the obtained measurements, the cytotoxicity (%) of each evaluation compound treatment group was calculated and used as a comparative value, with the untreated group set at 0% and the cell lysis buffer treatment group set at 100%. The test was performed in triplicate in three wells, and the average value was used. The test was considered valid if clear cytotoxicity was observed in the positive control compound treatment group and almost no cytotoxicity was observed in the negative control compound treatment group.
[0162] (4) Test Results (Discussion) The test results for cytotoxicity (%) are shown in the table below.
[0163]
[0164] The cytotoxicity of all the example compounds in the above table was equal to or less than that of risperidone, the negative control. Furthermore, the quaternary ammonium compound Reference Example 4 (REX 4) exhibited stronger cytotoxicity than the positive control Reference Example 3 (REX 3). This indicates that the example compounds have lower cytotoxicity than Reference Example 4.
[0165] Test for Confirmation of Conversion to Brexpiprazole The conversion of the evaluation compound to brexpiprazole in buffer (i.e., the stability of the evaluation compound) was evaluated.
[0166] The compound of Example 1 was dissolved in acetonitrile / water (1:1, v / v) to a concentration of 10 mmol / L, and further diluted with acetonitrile / water (1:1, v / v) to a concentration of 100 μmol / L before use.
[0167] The other example compounds and the compounds of Reference Examples 5 to 7, except for the compounds described below, were each dissolved in DMSO to a concentration of 10 mmol / L and then diluted with acetonitrile to 100 μmol / L before use. The compounds of Examples 52, 95, 96, 117, and 130 (EX 52, EX 95, EX 96, EX 117, and EX 130) were dissolved in acetonitrile / water (8:2, v / v) to 10 mmol / L and then diluted with acetonitrile to 100 μmol / L before use. The compound of Example 97 (EX 97) was dissolved in acetonitrile / water (8:2, v / v) to 10 mmol / L and then diluted with acetonitrile / water (8:2, v / v) to 100 μmol / L before use. The compounds of Examples 15 and 116 (EX 15 and EX 116) were dissolved in DMSO to 1 mmol / L and then diluted with acetonitrile to 100 μmol / L before use.
[0168] These evaluation compound solutions were prepared immediately before use.
[0169] The reaction was carried out by preparing a reaction solution so that the final concentrations of each component were as follows. The test was also carried out in duplicate.
[0170] Composition Final concentration Tris-HCl buffer (pH 7.5) 50 mmol / L Magnesium chloride 5 mmol / L Test compound solution 1 μmol / L
[0171] For the compounds of Examples 1 to 8, 10 to 19, 26 to 27, 37, 50, 87 to 89, 91, 116, 121, 123, 150, and 151 (EX1 to 8, 10 to 19, 26 to 27, 37, 50, 87 to 89, 91, 116, 121, 123, 150, and 151) and the compounds of Reference Examples 5 to 7 (REX5 to 7), a reaction solution (198 μl) without the test compound was preincubated at 37°C for 3 minutes, followed by the addition of the test compound solution (2 μl) and stirring at 37°C to initiate the reaction. The reaction was terminated 0 or 60 minutes after the start of the reaction by adding a reaction stop solution (1000 μl) consisting of acetonitrile / isopropanol (4:1, v / v) containing an internal standard and stirring. The 0-minute reaction sample (198 μl) was prepared by adding the reaction stop solution (1000 μl) followed by the evaluation compound (2 μl). The sample after the reaction was stopped was used as the measurement sample. Standard curve samples of the same composition were prepared (final concentrations of the evaluation compound and brexpiprazole: 0.01, 0.1, and 1 μmol / L, except that the 0-minute reaction sample of the evaluation compound was also used as the 1 μmol / L standard curve sample). Compounds of Examples 24-25, 28-29, 32-36, 40-49, 51-60, 62-64, 66-77, 80-86, 90, 92-111, 113, 115, 117-120, 122, 124-130, 132-147, 152-160 (EX24-25, 28-29, 32-36, 40-49, 51-60, 62-64, 66 For the samples (~77, 80-86, 90, 92-111, 113, 115, 117-120, 122, 124-130, 132-147, 152-160), a reaction solution (148.5 μL) without the evaluation compound was preincubated at 37°C for 3 minutes, followed by the addition of the evaluation compound solution (1.5 μL) and stirring at 37°C. The reaction was stopped at 0 or 60 minutes after the start of the reaction by adding and stirring a reaction stop solution (600 μL) consisting of acetonitrile / isopropanol (4:1, v / v) containing an internal standard. However, the 0-minute reaction sample (148.5 μL) was prepared by adding the reaction stop solution (600 μL) followed by the evaluation compound (1.5 μL). The sample after the reaction was stopped was used as the measurement sample.Samples for the calibration curve of the same composition were prepared (final concentrations of the evaluation compound and brexpiprazole: 0.01, 0.1, 1 μmol / L, except that the 0-minute reaction sample of the evaluation compound alone was also used as a 1 μmol / L calibration curve sample).
[0172] For the compounds of Examples 1 to 8, 10 to 19, 26 to 27, 37, 50, 87 to 89, 91, 116, 121, 123, 150, and 151 (EX1 to 8, 10 to 19, 26 to 27, 37, 50, 87 to 89, 91, 116, 121, 123, 150, and 151) and the compounds of Reference Examples 5 to 7 (REX5 to 7), the obtained measurement samples and calibration curve samples were centrifuged, and the supernatants were appropriately diluted with a mixture of acetonitrile / isopropanol (4:1, v / v) and injected into a liquid chromatograph-tandem mass spectrometer (HPLC: Shimadzu Corporation Prominence UFLC system, MS: SCIEX API4000) to measure the evaluation compounds, brexpiprazole, and internal standards. Examples 24-25, 28-29, 32-36, 40-49, 51-60, 62-64, 66-77, 80-86, 90, 92-111, 113, 115, 117-120, 122, 124-130, 132-147, 152-160 compounds (EX24-25, 28-29, 32-36, 40-49, 51-60, 62-64, 66-77, 80-86, 90, 92-111, 113, For the samples (115, 117-120, 122, 124-130, 132-147, 152-160), the obtained measurement samples and calibration curve samples were centrifuged, and the supernatant was appropriately diluted with ultrapure water and a mixture of acetonitrile and isopropanol (4:1, v / v) so that the ultrapure water content was 20%. The measurement sample was then injected into a liquid chromatograph-tandem mass spectrometer (HPLC: Shimadzu Corporation Prominence UFLC system, MS: SCIEX Triple Quad 4500) to measure the evaluation compound, brexpiprazole, and internal standard. Ionization was performed using electrospray ionization with positive ionization detection, and selective reaction detection was performed using set precursor ions and product ions. The internal standard used was the deuterated form of brexpiprazole (Brexpiprazole-d8), etc. The remaining amount of the evaluation compound and the amount of brexpiprazole produced in the 0-minute reaction sample and the 60-minute reaction sample were calculated.
[0173] The difference between the remaining amount of the evaluation compound in the 0-minute reaction sample and the 60-minute reaction sample was taken, and the amount of decrease in the 60-minute reaction sample was calculated. Based on this change in the evaluation compound, the stability of the evaluation compound in the buffer was evaluated.
[0174] The conversion to brexpiprazole in the 60-minute reaction sample was evaluated from the amount of brexpiprazole produced in the 60-minute reaction sample. When brexpiprazole was detected in the 0-minute reaction sample, the difference between the amounts of brexpiprazole produced in the 0-minute reaction sample and the 60-minute reaction sample was taken to calculate the increase in the 60-minute reaction sample. The stability of the evaluation compound in the buffer was evaluated based on this change in brexpiprazole.
[0175] The test results are shown in the table below. The reduced concentration (µmol / L) of the evaluated compound and the produced concentration (µmol / L) of brexpiprazole were tested in duplicate, and the average values were used.
[0176]
[0177] [Discussion] The Example compounds are quaternary ammonium compounds like the Reference Compounds (Reference Examples 5, 6, and 7), but are stable in buffer and do not convert to brexpiprazole. On the other hand, the Reference Compounds are clearly observed to decompose into brexpiprazole. This indicates that the Example compounds of the present application are stable when formulated and may be stably handled as prodrugs of brexpiprazole.
[0178] Preparation of Pharmaceutical Composition of Example 1 Compound - 1 (Example A) (1.25 mg / mL Solution Formulation of Example 1 Compound) Example 1 compound was dissolved at a concentration of 1.25 mg / mL in phosphate-buffered saline (pH 7.4) containing 10% dimethyl sulfoxide and 0.09% polysorbate 80. (Example B) (0.5 mg / mL Solution Formulation of Example 1 Compound) Approximately 80% of the final volume of water for injection was weighed out, and D-mannitol and monosodium phosphate monohydrate were added and stirred to dissolve. Example 1 compound was then added and stirred to disperse. 1 M sodium hydroxide solution was added little by little to dissolve Example 1 compound, and the pH was adjusted to 8.0. The remaining amount of water for injection was added to reach the final volume, and the solution was then sterile-filtered using a 0.2 μm PVDF membrane filter. The composition per mL is shown in the table below. (Example C) (5.0 mg / mL solution formulation of Example 1 compound) Approximately 80% of the final preparation amount of water for injection was weighed out, and D-mannitol and monosodium phosphate monohydrate were added and stirred to dissolve. The Example 1 compound was then added and stirred to disperse. 1 M sodium hydroxide solution was added little by little to dissolve the Example 1 compound, and the pH was adjusted to 8.9. The remaining amount of water for injection was added to reach the final preparation amount, and the solution was then sterile-filtered using a filtration filter (0.2 μm, PVDF membrane). The composition per 1 mL is shown in the table below.
[0179] Evaluation of the Pharmaceutical Composition of Example A The pharmaceutical composition of Example A (1.25 mg / mL solution formulation of the compound of Example 1) was subcutaneously administered to male rats, and the plasma concentrations of the compound of Example 1 and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The breeding environment was as follows: food and water intake: unlimited, number of rats per cage: 3, temperature: 23±2°C, humidity: 60±10%, lighting hours: 7:00-19:00. The rats were anesthetized with isoflurane and subcutaneously administered to the back using a plastic syringe. The dose was 1.25 mg / kg. Approximately 0.3 mL of blood was collected from the jugular vein 5, 10, 20, 30, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after administration. The blood was promptly heparinized and ice-cooled, and the plasma was separated by centrifugation. The compound concentration was quantified by LC-MS. Figure 1 shows the time course of plasma drug concentration following subcutaneous administration of the pharmaceutical composition of Example A (1.25 mg / mL solution formulation of Example 1 compound). Since Example 1 compound and brexpiprazole were detected in plasma 5 minutes after administration, it is believed that Example 1 compound rapidly reaches the blood and systemic circulation from the subcutaneous phase, and brexpiprazole is rapidly produced in the blood. Furthermore, the peak plasma concentration of brexpiprazole was reached 1 hour after subcutaneous administration, suggesting that rapid pharmacological effects are expected. Therefore, a liquid pharmaceutical composition containing Example 1 compound rapidly produces brexpiprazole in the body after subcutaneous administration, and the produced brexpiprazole exerts its pharmacological effects, making it a useful pharmaceutical composition for treating symptoms, for example, in patients with acute schizophrenia or agitation due to Alzheimer's dementia.
[0180] Preparation of Pharmaceutical Composition of Example 1 Compound - 2 (Example D) (150 mg / g Aqueous Suspension Formulation of Example 1 Compound) Carboxymethylcellulose sodium (CMC-Na) (1.0% (w / w)), sodium chloride (0.9% (w / w)), and sodium dihydrogen phosphate monohydrate (0.074% (w / w)) were dissolved in water for injection to achieve the following concentrations. The pH of the solution was adjusted to 6.8 with sodium hydroxide, and the resulting solution was sterile filtered using a 0.2 μm PES membrane filter in a clean bench. Example 1 compound was added to this solution to achieve the indicated concentration (150 mg / g) to prepare a primary aqueous suspension. An autoclave-sterilized magnetic stirrer and 1 g of autoclave-sterilized zirconia beads with a diameter of 1.0 mm were added to this primary aqueous suspension, and the container was sealed. The mixture was stirred at 5°C for 21 hours and wet-pulverized to prepare a secondary aqueous suspension. The secondary aqueous suspension was collected from the zirconia bead mixture using a sterilized pipette. The particle size distribution of this secondary aqueous suspension was measured using a laser diffraction particle size distribution analyzer, SALD-3100 (Shimadzu Corporation). After 1 minute of ultrasonic irradiation using the built-in device, measurements were performed with a refractive index setting of 2.00 - 0.20i, and the average particle size was found to be 1.9 μm.
[0181] Evaluation of the Pharmaceutical Composition of Example D The pharmaceutical composition of Example D (150 mg / g aqueous suspension formulation of the compound of Example 1) was subcutaneously administered to male rats, and the plasma concentrations of the compound of Example 1 and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The breeding environment was as follows: food and water access: unlimited, number of rats per cage: 3, temperature: 23 ± 2°C, humidity: 60 ± 10%, lighting time: 7:00-19:00. The rats were anesthetized with isoflurane and subcutaneously administered to the back using a plastic syringe. The dose was adjusted to 25 mg / kg of brexpiprazole equivalent. Approximately 0.5 mL of blood was collected 2 hours after administration and on days 1, 3, 6, 9, and 14. The blood was immediately heparinized and cooled on ice, and the plasma was separated by centrifugation. The compound concentrations were quantified by LC-MS. Figure 2 shows the time course of plasma drug concentrations after subcutaneous administration of the pharmaceutical composition of Example D (150 mg / g aqueous suspension formulation of Example 1 compound) to male rats. When the pharmaceutical composition of Example D was administered subcutaneously, Example 1 compound and brexpiprazole were detected 2 hours after administration. Plasma brexpiprazole concentrations remained approximately constant from 2 to 24 hours after administration, but rapidly decreased from the third day onwards. Therefore, the aqueous suspension injection of Example 1 compound is expected to exert its pharmacological effect by maintaining brexpiprazole in plasma for about one day after subcutaneous administration. From the above, it is expected that a pharmaceutical composition prepared by suspending the compound of Example 1 in injection water will rapidly produce brexpiprazole in the body after subcutaneous administration, maintain a substantially constant plasma brexpiprazole level for one day after administration, and exhibit the pharmacological action of brexpiprazole. Therefore, it is expected to be a useful pharmaceutical composition as a convenient daily subcutaneous injection for patients with schizophrenia, depression, or agitation due to Alzheimer's disease who tend to refuse medication, for example.
[0182] Preparation of Pharmaceutical Composition of Example 1 Compound - 3 (Example E) (159 mg / g Zinc Salt Aqueous Suspension Formulation of Example 1 Compound) Carboxymethylcellulose sodium (CMC-Na) (1.0% (w / w)), D-mannitol (4.5% (w / w)), and sodium dihydrogen phosphate monohydrate (0.074% (w / w)) were dissolved in water for injection to a concentration of these components, and the pH of the solution was adjusted to 6.0 with sodium hydroxide. The resulting solution was sterile filtered using a 0.2 μm PES membrane filter in a clean bench to prepare a suspension medium. 757 mg of the zinc salt of Example 1 compound and 3873 mg of the suspension medium were weighed and mixed. The average particle size of the resulting suspension was 3.9 μm. The average particle size was measured using a laser diffraction particle size distribution analyzer SALD-3100 (Shimadzu Corporation) with a refractive index set to 2.00-0.20i after 1 minute of ultrasonic irradiation using the built-in device.
[0183] Evaluation of the Pharmaceutical Composition of Example E The pharmaceutical composition of Example E (159 mg / g zinc salt aqueous suspension of Example 1 compound) was subcutaneously administered to male rats, and the plasma concentrations of Example 1 compound and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The breeding environment was as follows: food and water intake: unlimited, number of rats per cage: 3, temperature: 23 ± 2°C, humidity: 60 ± 10%, lighting time: 7:00-19:00. The rats were anesthetized with isoflurane and subcutaneously administered to the back using a glass syringe. The dose was adjusted to 25 mg / kg of brexpiprazole. Approximately 0.5 mL of blood was collected 2 hours after administration and on days 1, 3, 6, 9, 14, 21, and 28. The blood was promptly heparinized and ice-cooled, and the plasma was separated by centrifugation. The compound concentration was quantified by LC-MS. Figure 3 shows the time course of plasma drug concentrations after subcutaneous administration of the pharmaceutical composition of Example E (159 mg / g zinc salt aqueous suspension formulation of Example 1 compound) to male rats. When the pharmaceutical composition of Example E was administered subcutaneously, Example 1 compound and brexpiprazole were detected 2 hours after administration, and the maximum plasma drug concentration was reached at 24 hours. Compared to Example D, the plasma drug concentrations at 2 and 24 hours were suppressed, confirming the sustained-release effect of the zinc salt. A constant plasma drug concentration was maintained from day 3 onward until day 14. Therefore, the aqueous suspension injection of the zinc salt of Example 1 compound is expected to exert its pharmacological effect by maintaining plasma brexpiprazole for 1 to 14 days after subcutaneous administration. From the above, it is expected that a pharmaceutical composition prepared by suspending the zinc salt of the compound of Example 1 in injection water will rapidly produce brexpiprazole in the body after subcutaneous administration, maintain brexpiprazole in plasma for several days or more after administration, and exhibit the pharmacological action of brexpiprazole. Therefore, it is expected to be a useful pharmaceutical composition as a subcutaneous injection for daily to weekly use, which is highly convenient for patients with schizophrenia, depression, and agitation due to Alzheimer's disease who tend to refuse medication.
[0184] Preparation of Pharmaceutical Composition of Example 1 Compound - 4 (Example F) (Liquid Crystal / Lipid Gel Formulation of 150 mg / g of Example 1 Compound) Soybean lecithin (soybean phosphatidylcholine; SPC (LIPOID S 100, Lipoid)) and glycerol dioleate (GDO (Merck, Isomeric Mix 1,2 / 1,3-GDO)) were added to ethanol, and the mixture was heated to 40-50°C to dissolve. The solution was filtered through a 0.2 μm disk filter, and Example 1 compound was added to the filtrate, which was then mixed with a vortex to homogenize. The composition of the resulting formulation is shown in the table below. Example G (Liquid Crystal / Lipid Gel Formulation of 159 mg / g Zinc Salt of Example 1 Compound) Soybean lecithin (SPC (LIPOID S 100, Lipoid)) and glycerol dioleate (GDO (Merck, Isomeric Mix 1,2 / 1,3-GDO)) were added to a mixture of DMSO and ethanol and dissolved by heating at 40-50°C. The solution was filtered through a 0.2 μm disc filter, and the zinc salt of Example 1 compound was added to the filtrate, which was then mixed with a vortex mix to homogenize. The composition of the resulting formulation is shown in the table below.
[0185] Evaluation of the Pharmaceutical Compositions of Examples F and G Viscosity Measurement Measurements were performed using a rheometer, Discovery Hybrid Rheometer (DHR)-2 (manufacturer: TA Instruments), and the viscosity of Formulation F at a shear rate of 9,000-10,000 (1 / s) was 402 mPa s. The viscosity measurement conditions were as follows: Shear rate measurement range: 0.1 → 10,000 (1 / s); Measurement temperature: 20°C; A 20 mm flat plate was used; Gap: 50 μm (40 mm flat plate).
[0186] Changes in Plasma Drug Concentration: The pharmaceutical compositions (formulations) of Examples F and G were subcutaneously administered to male rats, and the plasma concentrations of the compound of Example 1 and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The breeding environment was as follows: food and water intake: unlimited, number of rats per cage: 3, temperature: 23±2°C, humidity: 60±10%, lighting time: 7:00-19:00. The rats were anesthetized with isoflurane and subcutaneously administered to the back using a glass syringe. The dose was adjusted to 25 mg / kg of brexpiprazole. Approximately 0.5 mL of blood was collected 2 hours after administration and on days 1, 3, 6, 9, 14, 21, and 28. The blood was immediately heparinized and cooled on ice, and the plasma was separated by centrifugation. Compound concentrations were quantified by LC-MS. The time course of plasma drug concentrations after subcutaneous administration of the pharmaceutical compositions of Examples F and G to male rats is shown in Figures 4 and 5, respectively. Example F maintained a relatively high plasma brexpiprazole concentration early after administration, and brexpiprazole was detected at a relatively high concentration in plasma even 14 days after administration, maintaining the plasma brexpiprazole concentration for more than 14 days. Compared with the aqueous suspension of Example D, the plasma drug concentration was further suppressed, confirming the sustained-release effect of the liquid crystal / lipid gel formulation.
[0187] In Example G, a relatively high plasma brexpiprazole concentration was maintained early after administration, and even 21 days after administration, a relatively high concentration of brexpiprazole was detected in the plasma, and the plasma brexpiprazole concentration was maintained for more than 21 days. Compared with the aqueous suspension of zinc salt in Example E, the plasma drug concentration was further suppressed, confirming the sustained-release effect of the liquid crystal / lipid gel formulation. From these results, it is believed that the release of Example 1 compound from the formulation can be controlled by combining an appropriate sustained-release base with a metal salt, and that by converting Example 1 compound to brexpiprazole in the body, it will be possible to maintain brexpiprazole exposure in the blood at a level that will produce a therapeutic effect for 14 to 21 days or more. A pharmaceutical composition that forms a liquid crystal / lipid gel of Example 1 compound or a salt thereof maintains a relatively high blood brexpiprazole concentration early after administration, and therefore can maintain blood drug concentrations without the need for concomitant use of an oral agent or shortening the injection interval to supplement the blood drug concentration at the start of treatment with a long-acting injectable agent, and is therefore expected to be a useful pharmaceutical composition for preventing relapse of, for example, schizophrenia, etc.
[0188] Preparation of Pharmaceutical Composition of Example 1 Compound - 5 (Examples H, I, J, K, L, M, N, O) (300-400 mg / g Microspheres of Example 1 Compound) In each composition shown in the table below, the Example 1 compound and biodegradable polymer poly(lactide-co-glycolide) copolymers (lactic acid-co-glycolic acid copolymers: PLGA) Resomer RG505, Resomer RG504, Resomer RG503, Resomer RG502, Resomer RG752H or Lactel 85:15 Poly (DL-lactide-co-glycolide), Ester Terminated (PLGE) Inherent Viscosity Range (IV): 0.76-0.85 dL / g (Resomer and Lactel are all Evonik) were dissolved in dichloromethane (Fujifilm Wako Pure Chemical Industries) and acetic acid (Fujifilm Wako Pure Chemical Industries) to prepare an oily phase. Polyvinyl alcohol 40-88 (Merck) was dissolved in purified water to a concentration of 0.5% to prepare the aqueous phase (continuous phase). The aqueous phase was homogenized at 2000-3000 rpm using a TK Robomix (Primix) equipped with a homogenizer, while the oil phase was added dropwise. The aqueous phase was then stirred at 200-500 rpm with a stirrer for 5 hours while being submerged in water to prepare microspheres. The microspheres were then observed under a polarizing microscope. If necessary, additional washing procedures were performed after submerged drying, using alkalis such as 99.5% ethanol or 1N sodium hydroxide solution. After submerged drying, the microspheres were filtered by aspiration through a filter fitted with a 20 μm nylon mesh filter, and the aqueous phase was removed. The microspheres were then collected by filtration using approximately 1 / 5 the volume of purified water used for the aqueous phase, to thoroughly wash away the PVA. The collected microspheres were collected in a Falcon tube, frozen in a freezer at -20°C or below, and lyophilized using a Lyostar-3 freeze dryer (SP Scientific) to collect powdered microspheres. The molar ratio of lactic acid and glycolic acid, characteristics, weight-average molecular weight, and inherent viscosity range (dL / g) of each PLGA used are as follows:Resomer RG505 lactide:glycolide 50:50, ester terminated, Mw 54,000-69,000, Resomer RG504 lactide:glycolide 50:50, ester terminated, Mw 38,000-54,000, 0.45-0.60 Resomer RG503 lactide:glycolide 50:50, ester terminated, Mw 24,000-38,000, 0.32-0.44 Resomer RG502 lactide:glycolide 50:50, ester terminated, Mw 7,000-17,000, 0.16-0.24 Resomer RG752H lactide:glycolide 75:25, acid terminated, Mw 4,000-15,000, 0.14-0.22 Lactel 85:15 PLGE IV 0.76-0.85 lactide:glycolide 85:15, ester terminated, unknown, 0.76-0.85.
[0189] Evaluation of the Pharmaceutical Compositions of Examples H to O Polarizing Microscope Observation The microspheres of Examples I, J, and K after drying in liquid were observed under a polarizing microscope. The results are shown in Figures 6, 7, and 8. It was confirmed that microspheres were formed in all cases.
[0190] Measurement of Average Particle Size: The resulting microspheres were suspended in a 0.5% carmellose sodium solution, and particle size was measured by laser diffraction / scattering using a laser diffraction particle size analyzer, SALD-3100 (Shimadzu Corporation). Purified water was used as the solvent, and either a batch cell or a circulation cell was used. The stirring speed was set to maximum for the batch cell, and the circulation speed was set to 5 for the circulation cell. The formulation was added dropwise to the purified water until the optimal concentration was reached, and the average particle size was measured with a refractive index of 2.00 - 0.20i. The results are shown in the table below. The average particle size was 50-85 μm, which was suitable for the manufacturing example, as it maintained blood concentrations for more than one month. Drug Encapsulation Rate 20 mg of the obtained microspheres was dissolved in 10 mL of dimethyl sulfoxide / acetic acid (4 / 1) solution, and 1 mL of this solution was diluted 10 times with acetonitrile to prepare a test solution, and the drug encapsulation rate within the microspheres was measured by HPLC. The encapsulation rate of each of the prepared manufacturing examples was measured by HPLC. The results are shown in the table below. As shown in the table below, the encapsulation rate of Examples H to O was 80% or higher. Since the microspheres are prepared through a drying process, the denominator in the above encapsulation rate (%) calculation formula (theoretical concentration of the compound of Example 1 in the microspheres) essentially represents the concentration of the compound of Example 1 relative to the total amount of the compound of Example 1 and PLGA charged.
[0191] Plasma Drug Concentration Changes. Medium-chain triglyceride (MCT, obtained from Croda, used as a solvent) was added to the microsphere powders of Examples H, J, K, and L to prepare MCT suspensions of Examples H, J, K, and L at 300 mg / mL. These suspensions were subcutaneously administered to male rats, and the plasma concentrations of Example Compound 1 and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The rearing environment was as follows: food and water access: unlimited, 2-3 rats per cage, temperature: 23±2°C, humidity: 60±10%, lighting: 7:00-19:00. Rats were anesthetized with isoflurane and subcutaneously administered to the back using a glass syringe. The dose of each formulation was adjusted to 25 mg / kg of brexpiprazole. After administration, 0.5 mL of blood was collected from the jugular vein over time. For Example H, blood was collected 2 hours, 1 day, 3 days, 6 days, 9 days, 14 days, 21 days, and 28 days after administration. For Examples J, K, and L, blood was collected 2 hours, 1 day, 3 days, 7 days, 10 days, 14 days, 21 days, 28 days, 35 days, 42 days, and 56 days after administration. The blood was heparinized immediately after collection and cooled on ice. Plasma was separated by centrifugation, and the concentrations of the example compounds and brexpiprazole were measured by LC-MS. The time course of plasma drug concentrations after subcutaneous administration of the pharmaceutical compositions of Examples H, J, K, and L to male rats is shown in Figures 9, 10, 11, and 12. In all cases, blood concentrations increased immediately after administration, and blood brexpiprazole concentrations persisted for more than one month.From these results, it was thought that by preparing microspheres containing the compound of Example 1 using an appropriate biodegradable polymer, it is possible to control the release of the compound of Example 1 from the formulation, and by converting the compound of Example 1 to brexpiprazole in the body, it is possible to maintain brexpiprazole exposure in the blood at a level at which a therapeutic effect can be exerted for more than one month.The pharmaceutical composition of microspheres of the compound of Example 1 maintains a relatively high blood brexpiprazole concentration in the early stages after administration, and therefore it is possible to maintain blood drug concentrations without the need for concomitant use of an oral agent or shortening the injection interval to supplement the blood drug concentration at the start of treatment with a long-acting injectable agent, and therefore it is expected to be a useful pharmaceutical composition for preventing relapse of, for example, schizophrenia, etc.
[0192] Preparation of Pharmaceutical Composition of Example 3 Compound (Example P) Carboxymethylcellulose sodium (CMC-Na) (1.23% (w / v)), sucrose (5.75% (w / v)), sodium dihydrogen phosphate monohydrate (0.12% (w / v)), and citric acid anhydrous (0.16% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of sodium hydroxide was added to adjust the pH to 5.0 to prepare a suspension medium. 712 mg of Example 3 compound was added to 3288 mg of the suspension medium and mixed to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 3 compound were milled by stirring with a stirrer (milling time: 8 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 3 compound was prepared.
[0193] Preparation of Pharmaceutical Composition of Example 10 Compound (Example Q) Carboxymethylcellulose sodium (CMC-Na) (0.796% (w / v)), sodium chloride (0.716% (w / v)), and sodium dihydrogen phosphate monohydrate (0.055% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of sodium hydroxide was added to adjust the pH to 6.0 to prepare a suspension medium. 816 mg of Example 10 compound was added to 3184 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 10 compound were milled by stirring with a stirrer (milling time: 80 minutes). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 10 compound was prepared.
[0194] Preparation of Pharmaceutical Composition of Example 12 Compound (Example R) Carboxymethylcellulose sodium (CMC-Na) (0.813% (w / v)), sodium chloride (0.732% (w / v)), and sodium dihydrogen phosphate monohydrate (0.056% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of sodium hydroxide was added to adjust the pH to 6.0 to prepare a suspension medium. 748 mg of Example 12 compound was added to 3252 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 12 compound were milled by stirring with a stirrer (milling time: 2 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 12 compound was prepared.
[0195] Preparation of Pharmaceutical Composition of Example 13 Compound (Example S) Carboxymethylcellulose sodium (CMC-Na) (0.805% (w / v)), sodium chloride (0.725% (w / v)), and sodium dihydrogen phosphate monohydrate (0.056% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of sodium hydroxide was added to adjust the pH to 6.0 to prepare a suspension medium. 780 mg of Example 13 compound was added to 3220 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 13 compound were milled by stirring with a stirrer (milling time: 3 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 13 compound was prepared.
[0196] Preparation of Pharmaceutical Composition of Example 44 Compound (Example T) Carboxymethylcellulose sodium (CMC-Na) (0.791% (w / v)), sodium chloride (0.712% (w / v)), and sodium dihydrogen phosphate monohydrate (0.055% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of sodium hydroxide was added to adjust the pH to 6.0 to prepare a suspension medium. 836 mg of Example 44 compound was added to 3164 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 44 compound were milled by stirring with a stirrer (milling time: 4 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 44 compound was prepared.
[0197] Preparation of Pharmaceutical Composition of Example 92 Compound (Example U) Carboxymethylcellulose sodium (CMC-Na) (0.803% (w / v)), sodium chloride (0.723% (w / v)), and sodium dihydrogen phosphate monohydrate (0.055% (w / v)) were dissolved in water for injection to achieve the following concentrations, and an appropriate amount of sodium hydroxide was added to adjust the pH to 6.0 to prepare a suspension medium. 788 mg of Example 92 compound was added to 3152 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 2 mm were added to the primary suspension, and the particles of Example 92 compound were milled by stirring with a stirrer (milling time: 24 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of Example 92 compound was prepared.
[0198] Preparation of Pharmaceutical Composition of Compound of Example 121 (Example V) Hydroxypropyl cellulose (HPC) (4.02% (w / v)), glycerin (2.01% (w / v)), and histidine (0.06% (w / v)) were dissolved in water for injection to a concentration of these components, and an appropriate amount of hydrochloric acid was added to adjust the pH to 7.0 to prepare a suspension medium. 784 mg of the compound of Example 121 was added to 3216 mg of the suspension medium, and the mixture was mixed and stirred to prepare a primary suspension. 4 g of zirconia beads with a diameter of 0.5 mm was added to the primary suspension, and the particles of the compound of Example 121 were milled by stirring with a stirrer (milling time: 24 hours). The zirconia beads were removed using a sterilized pipette, and an aqueous suspension formulation of the compound of Example 121 was prepared.
[0199] Evaluation of the Pharmaceutical Compositions of Examples P to V Measurement of Average Particle Size The particle sizes of the obtained aqueous suspension formulations were measured by laser diffraction / scattering method using a laser diffraction particle size distribution analyzer SALD-3100 (Shimadzu Corporation) with a refractive index setting of 2.00 - 0.20i. The results are shown in the table below.
[0200] Plasma Drug Concentration Changes. Aqueous suspensions of Examples P-V were administered subcutaneously to male rats, and the plasma concentrations of each example compound and brexpiprazole were measured. Male rats were purchased from Japan SLC Co., Ltd. at 7 weeks of age and used in the experiment after preliminary breeding. The breeding environment was as follows: food and water intake: unlimited, three rats per cage, temperature: 23±2°C, humidity: 60±10%, lighting: 7:00-19:00. Rats were anesthetized with isoflurane and subcutaneously administered to the back using a plastic or glass syringe. The dose of each formulation was adjusted to 25 mg / kg of brexpiprazole. After administration, 0.5 mL of blood was collected from the jugular vein at regular intervals. Blood samples were collected 2 hours, 1 day, 3 days, 6 days, 9 days, 14 days, 21 days, and 28 days after administration. After collection, the blood was immediately heparinized and kept on ice. To suppress hydrolysis in the samples, a phosphatase inhibitor cocktail (Nacalai Tesque) was added to a final concentration of 1% to blood samples from individuals administered Examples P-U, and 2-thenoyltrifluoroacetone (TTFA) was added to a final concentration of 10 mM to blood samples from individuals administered Example V. Plasma was separated by centrifugation, and the concentrations of each example compound and brexpiprazole were measured by LC-MS. Results are shown as the mean ± standard deviation of 3-5 cases. The time course of plasma drug concentrations after subcutaneous administration of the pharmaceutical compositions of Examples P, Q, R, S, T, U, and V to male rats is shown in Figures 13, 14, 15, 16, 17, 18, and 19. In all cases, brexpiprazole concentrations were significantly sustained compared to the pharmaceutical composition of Example D (aqueous suspension of the compound of Example 1), demonstrating sustained blood brexpiprazole concentrations for at least 2 to 4 weeks. From these results, it is believed that by subjecting the compound of Example 1 to an appropriate structural conversion, it is possible to control the release of the compound of Example 1 from the formulation, and by converting the compound of Example 1 to brexpiprazole in vivo, it is possible to maintain the exposure of brexpiprazole in the blood at a level at which a therapeutic effect can be exerted for 2 to 4 weeks or more. This pharmaceutical composition is expected to be useful, for example, in preventing relapse of schizophrenia, etc.
[0201] Dog Irritation Test Method: Male beagle dogs were purchased from Kitayama Labes Co., Ltd. at 5-7 months of age and used in the experiment after preliminary breeding. The breeding environment was as follows: Feeding: 250 g of solid feed once daily, Water: Unrestricted, Number of dogs per cage: 1, Temperature: 21-25°C, Humidity: 50-70%, Lighting: 7:00-19:00. Dogs were anesthetized with 25 mg / kg thiopental sodium intravenously. The test formulations were then administered subcutaneously to the back of the dog at a dose of 10 mg / kg per formulation using a plastic syringe. After 14 days of observation, the dogs were anesthetized with 25 mg / kg thiamylal sodium intravenously and sacrificed by exsanguination. Skin samples from the injection site were collected. The collected tissues were fixed in 10% neutral buffered formalin, stained with hematoxylin and eosin, and subjected to histopathological examination.
[0202] Results and Discussion For several example compounds, external observation and histopathological examination of the injection site during the observation period confirmed that the changes at the injection site were a physiological reaction to a foreign substance and that the irritation was within an acceptable range.
Claims
1. Formula (I): (In the formula, R 1 , R 2 Each independently represents -O - , -OR 4 , or -NR 4Na R 4Nb Indicates R 3 represents hydrogen or alkyl; R 4 , R 4Na , and R 4Nb each independently represents hydrogen, or an alkyl, alkenyl, alkadienyl, or alkynyl group which may have 1 to 3 substituents, and R 4 , R 4Na , and R 4Nb The alkyl represented by is a methylene group (-CH 2 -) is -O-, -S-, -CO-, -NH-, -SiR sia R sib - or -(CO)O- may be substituted, R sia and R sib are the same or different and each represents a hydrogen atom or C 1-6 Represents an alkyl group, 1 and R 2 Both are -OR 4 In the case of 1 and R 2 may be the same or different, 1 and R 2 Both are -NR 4Na R 4Nb In the case of 1 and R 2 may be the same or different.) A compound or a salt thereof represented by the following formula:
2. R 1 Ga-O - indicates R 2 -OR 4 , or -NR 4Na R 4Nb (R 4 , R 4Na , and R 4Nb The compound or salt thereof according to claim 1, wherein 3. Formula (I): (In the formula, R 1 Ga-O - indicates R 2 -OR 4 , or -NR 4Na R 4Nb Indicates R 3 is hydrogen or C 1-6 Represents an alkyl group; R 4 represents hydrogen or any one of the following (0-1) to (5): 4Na R 4Nb represents the following (i) or (ii): (0-1): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 alkenyl, (0-2): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 Alkadienyl, (0-3): halogen, hydroxy, C 1-6 Alkyl, and C 1-6 C optionally having 1 to 3 substituents selected from alkoxy 1-18 Alkynyl, (1-1): R 4a1 Indicates R 4a1 is -C n H 2n+1 , -C n H 2n-1 , -C n H 2n-3 , -C n H 2n -OH, -C n H 2n-2 -OH, or -C n H 2n-4 In the above formula, n is 1 to 24. However, -C n H 2n-1 Then n is 2 or more, -C n H 2n-3 Then n is 2 or more, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 - In this case, n is 2 or more.) (1-2): R 4a2 Indicates R 4a2 is -CHX 1 X 2 -C n-1 H 2n-2 -CHX 1 X 2 -C n-1 H 2n-4 -CHX 1 X 2 , or -C n-1 H 2n-6 -CHX 1 X 2 (In the above formula, n is 2 to 24. However, -C n-1 H 2n-4 -n is 3 or more, -C n-1 H 2n-6 -n is 3 or more. X 1 and X 2 are the same or different and each represents a hydrogen atom or a halogen atom (F, Cl, Br, or I). 1 and X 2 At least one of the groups represents a halogen. 4a3 Indicates R 4a3 is -C n H 2n -R 4-1 , -C n-1 H 2n-2 -CHR 4-1a R 4-1b , -C n H 2n-2 -R 4-1 , or -C n H 2n-4 -R 4-1 (In the above formula, n is 1 to 24. However, -C n H 2n-2 -n is 2 or more, -C n H 2n-4 - n is 2 or more. 4-1 is C 1-6 Alkoxy, -O-phenyl, or C 1-6 R represents a heterocyclic group which may be substituted with alkyl or halogen. 4-1a and R 4-1b , are the same or different, and are -C 1-3 Alkylene-C 1-3 or each of the same or different groups represents an alkoxy group; 1-3 Alkyl, or -CH 2 -CO-O-C 1-3 (2): R 4b Indicates R 4b is -(C p H 2p -O) q -C r H 2r -R 4-2 , -(C p H 2p -O) q -C r H 2r-2 -R 4-2 , -(C p H 2p-2 -O) q -C r H 2r -R 4-2 , or -(C p H 2p-2 -O) q -C r H 2r-2 -R 4-2 (In the above formula, p is 1 to 4, q is 1 to 4, and r is 1 to 4. However, C p H 2p-2 Then p is 2 or more, C r H 2r-2 In the formula, r is 2 or more. When q is 2 to 4, the 2 to 4 repeating structures each representing the number of repeats represented by q may be the same or different. 4-2 is a hydrogen atom, a hydroxyl, or 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (3): -C represents a cycloalkyl group, a phenyl group, a benzyl group, or a heterocyclic group, each of which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. α H 2α -C-O-R COO Or -C α H 2α -CO-O-CH 2 -R COO (α represents 1 to 10), and -R COO is a hydrogen atom, 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 Alkyl or C 1-6 Alkoxy or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (4): -C represents a cycloalkyl group, a phenyl group, a benzyl group, or a heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. β H 2β -O-C-O-R OCO (β represents 1 to 10), and -R OCO is R 4a1 , R 4b , or -C α H 2α -C-O-R COO or -C α H 2α —CO—NH—R COO , -C α H 2α -NH-CO-R COO , or -C α H 2α -NH-CO-OR COO or (-R COO is the same as above) or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (5): -C represents a cycloalkyl group, a phenyl group, a benzyl group, or a heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. γ H 2γ -O-CO-O-R OCOO (γ represents 1 to 10), and -R OCOO is a hydrogen atom, R 4a1 , R 4b , or -C α H 2α -C-O-R COO or (-R COO is the same as above) or C 1-6 Alkyl, C 1-6 Alkoxy, -C 1-3 Alkylene-C 1-3 (i): R represents a cycloalkyl group, a phenyl group, a benzyl group, or a heterocyclic group, which may be substituted with 1 to 3 substituents selected from alkoxy and nitro. 4Na and R 4Nb are the same or different, and each represents 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 (ii): R 4Na is a hydrogen atom; R 4Nb is 1 to 3 C 1-6 C optionally substituted with alkoxy 1-6 represents an alkyl group or -C α H 2α -C-O-R COO , or -C α H 2α -CO-NH-R COO (-R COO (wherein each R is the same as above) 4. The compound or salt thereof according to any one of claims 1 to 3, wherein the heterocyclic group is a group having a structure in which one hydrogen atom bonded to an atom constituting a heterocycle selected from furan, tetrahydropyran, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, pyrrole, imidazole, pyrazole, pyridine, pyrimidine, pyrazine, pyridazine, pyrrolidine, imidazolidine, thiophene, piperidine, piperazine, oxazole, isoxazole, oxadiazole, morpholine, indole, indazole, benzimidazole, and quinoline has been removed.
5. -OR 4 is R of the oxygen atom 4 The opposite side is indicated by * (*-OR 4 ) is any of the groups shown in the table below, -NR 4Na R 4Nb is R of the nitrogen atom 4Na R 4Nb The opposite side is indicated by * (*-NR 4Na R 4Nb ) is any of the groups shown in the following table:
3. The compound according to claim 1 or 2, or a salt thereof.
6. Formula (II): (In the formula, R 3 is hydrogen or C 1-6 R indicates alkyl 4 is hydrogen or optionally having 1 to 3 substituents; C 1-18 alkyl, each of the substituents being independently selected from halogen, hydroxy, C 1-6 Alkoxy, -O-(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , -(CO)NR 7 R 8 , -O(CO)R 9 , -O(CO)OR 10 , -O(CO)(CR 11 R 12 ) n (CO)OR 13 , C 3-7 R represents a cycloalkyl group or a heterocyclic group which may have a substituent; 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 Alkyl, or C 3-7 represents cycloalkyl, R 7 and R 8 are independently a hydrogen atom or C in which one or two methylene groups may be replaced by an oxygen atom or a nitrogen atom. 1-6 represents alkyl, R 7 and R 8 may be bonded to form a ring, R 11 and R 12 are independently 11 When there are multiple, each is independent, R 12 When a plurality of groups are present, each group independently represents a hydrogen atom or C. 1-16 wherein n is an integer of 1 to 10, or a salt thereof.
7. R 4 is hydrogen, or -(AY) m -R 14 A indicates C 1-18 represents an alkylene; Y represents a bond, —O—, —(CO)O—, —O(CO)O—, or —(CO)NH—; R 14 is hydrogen, C 1-18 The compound or salt thereof according to claim 6, wherein m is an alkyl, hydroxy, cycloalkyl, or heterocyclic group, and m is an integer of 0 to 5.
8. R 4 is hydrogen or optionally has one substituent; C 1-8 alkyl, each of the substituents being independently hydroxy, C 1-6 Alkoxy, -O-(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , -O(CO)R 9 , -O(CO)OR 10 , -O(CO)-A-(CO)OR 13 , or two C's 1-6 morpholinyl optionally having an alkyl group, n is an integer of 1 to 10, 5 , R 5a , R 6 , R 9 , R 10 , and R 13 are independently a hydrogen atom, C 1-16 Alkyl, a heterocyclic group which may have a substituent, or C 3-7 A represents cycloalkyl; 1-6 The compound or salt thereof according to claim 6, wherein: R represents an alkylene.
9. R 4 is hydrogen or optionally has one substituent; C 1-8 alkyl, each of the substituents being independently hydroxy, C 1-6 Alkoxy, -O-(CH 2 ) n -OR 5 , -O(CO)-(CH 2 ) n -OR 5a , -(CO)OR 6 , -O(CO)R 9 , -O(CO)-A-(CO)OR 13 , or one or two C 1-6 represents a heterocyclic group optionally having an alkyl group, n represents an integer of 1 to 10, 5 is C 1-6 Alkyl, R 5a is C 1-6 Alkyl, R 6 is C 1-6 Alkyl, R 9 is C 1-16 Alkyl, R 13 is C 1-6 Alkyl or C 1-6 Pyridyl optionally having alkyl, A is C 1-6 The compound or salt thereof according to claim 6, wherein: R represents an alkylene.
10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a salt thereof, and a pharma- ceutically acceptable carrier.
11. The pharmaceutical composition according to claim 6, which is in the form of a suspension, comprising a compound or a salt thereof according to any one of claims 1 to 9, a suspending agent, and a dispersion medium.
12. The pharmaceutical composition according to claim 11, wherein the particles of the suspension have an average particle size of 0.5 to 30 μm.
13. The pharmaceutical composition according to claim 11, wherein the particles of the suspension have an average particle size of 50 to 500 nm.
14. The pharmaceutical composition according to any one of claims 11 to 13, wherein the suspending agent is carboxymethylcellulose or a salt thereof, and the dispersing medium is a liquid containing water for injection.
15. A pharmaceutical composition comprising a viscous mixture of: a) a compound or salt thereof according to any one of claims 1 to 9; b) a plurality of liquid crystal forming lipids or gel forming lipids; and c) a biocompatible organic solvent, the pharmaceutical composition being a precursor formulation used to form a liquid crystal phase structure or a lipid gel upon contact with an aqueous fluid in a living body.
16. The pharmaceutical composition of claim 15, wherein the b) plurality of liquid crystal-forming or gel-forming lipids comprises b-1) at least one diacylglycerol and b-2) at least one phosphatidylcholine.
17. A pharmaceutical composition comprising a viscous mixture of: a) a compound according to any one of claims 1 to 9 or a salt thereof; b-1) at least one diacylglycerol; b-2) at least one phosphatidylcholine; and c) a biocompatible organic solvent.
18. Microspheres containing the compound or salt thereof according to any one of claims 1 to 9 as an active ingredient.
19. The microsphere according to claim 18, comprising a compound according to any one of claims 1 to 9 and a biodegradable polymer.
20. The microsphere according to claim 19, wherein the biodegradable polymer is at least one selected from the group consisting of polylactic acid and lactic acid-glycol copolymers.
21. The microsphere according to any one of claims 18 to 20, having an average particle size of 5 to 150 µm.
22. A pharmaceutical composition comprising the microspheres according to any one of claims 18 to 21 in a suspended state.
23. A pharmaceutical composition comprising the microspheres according to any one of claims 18 to 21 suspended in oil.
24. The pharmaceutical composition of claim 23, wherein the oil is a medium chain triglyceride.
25. A pharmaceutical composition according to any one of claims 10 to 17 and 22 to 24, which is used for intramuscular or subcutaneous administration.
26. A pharmaceutical composition according to any one of claims 10 to 17 and 22 to 25, for use in the prevention and / or treatment of a central nervous system disease.
27. The central nervous system disease is schizophrenia, treatment-resistant, refractory or chronic schizophrenia, ataxic affective disorder, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson's disease, cognitive impairment 27. The pharmaceutical composition according to claim 26, wherein the central nervous system disorder is selected from the group consisting of cognitive impairment associated with a neurodegenerative disease, cognitive impairment caused by a neurodegenerative disease, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, intractable or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's syndrome, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome, impulsive symptoms associated with dementia and borderline personality disorder.
